Scientific Programme

Wednesday, 05 May 2021

Poster Sessions
13:00 - 20:30

Poster presentations (available on-demand)

Vanguard Poster

P-001  Is it the end of road for invasive neurological assessment in acute liver failure?
Swapnil Dhampalwar (Gurugram, India)

P-002  Prolonged functional human 3D-liver-organoids as an In Vitro liver disease model
Wenjun Zhang, Dr (Indianapolis, United States)

P-003  Simultaneous liver-kidney transplantation is associated with improved survival compared to liver transplant alone for candidates with renal dysfunction at the time of transplant
Kyle Jackson (Baltimore, United States)

P-004  Selection and perioperative outcome of sequential or combined coronary artery bypass surgery with live donor liver transplant
Amit Rastogi (Gurugram, India)

P-005  Left lobe living donor liver transplantation using rapid procedure in a cirrhotic patient with hepatocellular carcinoma with a GRWR of 0.35
Deniz Balci, MD, PhD (Ankara, Turkey)

P-006  Preliminary results of a single center experience: alpha-fetoprotein and 18F-FDG standard uptake value predict tumor recurrence after LT for HCC with portal vein tumor thrombosis
Zhe Yang (Hangzhou, China)

P-007  Liquid biopsy application in the era of transplant oncology
Alessandra Bertacco, MD PhD student (New Haven, United States)

P-008  Circulating cancer stem cells in hepatocellular carcinoma: a pilot study of prediction for tumor recurrence after living donor liver transplantation
Hyeo Seong Hwang (Seoul, Korea, Republic of)

P-009  Indications of post-liver transplantation early-phase systemic inflammatory cytokines on hepatic injury and outcomes of hepatocellular carcinoma recipients
Kevin Tak-Pan Ng, PhD (Hong Kong, China)

Basic Science/Translational Research

P-011  Production and characterisation of acellular human liver matrix: potential auxiliary liver graft
Abdul Rahman Hakeem (Chennai, India)

P-012  Oxidative stress and inflammasome response in fatty liver graft preservation
Arnau Panisello-Rosello (Barcelona, Spain)

P-013  IGL2 as a new perfusate for liver graft HOPE preservation
Arnau Panisello-Rosello (Barcelona, Spain)
Scientific Programme

P-014  Increased level of serum cholesterol and apoptosis together induces the development of liver fibrosis and early allograft loss
        B. Handan Ozdemir (Ankara, Turkey)

P-015  Neutrophil-to-lymphocyte ratio predicts acute cellular rejection in living donor liver transplantation
        Boram Lee (Gyeonggi-do, Korea, Republic of)

P-016  Investigation the relation of factor VII-related autophagy protein ATG14 to poor prognosis of hepatocellular carcinoma patients with lymphopenia after liver transplantation
        Chih-Che Lin, Associate Professor (Kaohsing, Taiwan, Republic of China)

P-017  Comparative proteomics analysis identifies L-FABP as a putative biomarker of graft injury during liver transplantation using the iTRAQ/MRM approach
        Maogen Chen (Guangzhou, China)

P-018  Protease-activated receptor 2 down-regulated dendritic cells exhibit immature properties and prolong heart allograft survival
        Maogen Chen (Guangzhou, China)

P-019  Real time viability assessment during normothermic machine perfusion with resonance Raman spectroscopy
        Reinier J de Vries (Boston, United States)

P-020  Rouleaux formation in human livers during normothermic machine perfusion increases vascular resistance and impedes viability
        Siavash Raigani (Boston, United States)

P-021  Synergistic anticancer effect of metformin in combination with immunosuppressant on hepatocellular carcinoma cell lines
        Suk-Won Suh (Seoul, Korea, Republic of)

P-022  A single-cell transcriptome atlas of 15 adult human organs
        Zhiyong Guo (Guangzhou, China)

P-023  The establishment of the first patient-derived whole organ model for primary liver cancer by normothermic machine perfusion technique
        Zhiyong Guo (Guangzhou, China)

P-024  Selective de-endothelialization of rat Liver xenografts using a novel LPS/RECA-1 conjugate
        Amir Sadek (Baltimore, United States)

P-025  Cytomegalovirus specific polyfunctional T-cells control CMV reactivation after liver transplantation
        Ângela Carvalho-Gomes, PhD (Valencia, Spain)

P-026  3D model for colorectal liver metastases microenvironment
        Angela M Chen, MD (Indianapolis, IN, United States)

P-027  3D bioprinted intrahepatic cholangiocarcinoma model and 7-day perfusion with gemcitabine and cisplatin: modeling the tumor microenvironment and response to chemotherapy
        Angela M Chen, MD (Indianapolis, IN, United States)

P-028  Biomarkers AFP in combination with AFP-L3 and DCP predicts tumor progression in treatment naive HCC patients
        Kelley Nunez (New Orleans, United States)
P-029  Inheritance features of CYP3A5 polymorphism in the Kazakh population
Bibigul Ilyassova, MD, PhD (Almaty, Kazakhstan)

P-030  LincRNA00844 inhibits MAPK signaling to suppress hepatocellular carcinoma progression via targeting AZGP1
Bingyi Lin (Hangzhou, China)

P-031  Identification of novel gene targets inducing resistance in liver ischemia reperfusion injury by CRISPR screening
Cem Kuscu (Memphis, United States)

P-032  PIVKA-II and biochemical parameters in patients with hepatocellular carcinoma on waiting list for liver transplantation
Felipe Alconchel (Murcia, Spain)

P-033  Liver-derived exosomes in liquid biopsies: advantage before liver transplantation - a pilot study
Fuat Aksoy (Bursa, Turkey)

P-034  Unique genomic & proteomic profile of liver mesenchymal stromal cells is associated with their superior immunomodulatory properties
Furkan Yigitbilek (Rochester, United States)

P-035  Serum cytokine profile after extended liver resection and liver transplantation
Hans-Michael Tautenhahn, PD Dr. med. (Jena, Germany)

P-036  Mycophenolate Mofetil attenuates liver fibrosis via promoting macrophage migration to liver by reducing macrophage migration inhibitory factor ligand CD74 expression
Hao Li (Changsha, China)

P-037  TGR5/Cathepsin E signaling regulates macrophage innate immune activation in the sterile inflammatory liver injury
Haoming Zhou (Nanjing, China)

P-038  Dynamics of IgG subclass as a mechanism of desensitization using rituximab for presensitized patients undergoing LDLT
Hiroto Egawa, MD, PhD (Tokyo, Japan)

P-039  The liver regenerative effect of Substance P after major hepatectomy in rat models
Hyung Joon Ahn, Ph.D. (Seoul, Korea, Republic of)

P-040  Macrophage Nogo-B promotes liver inflammatory injury by MST1-mediated Hippo-YAP signaling
Jianhua Rao (Nanjing, China)

P-041  Changes in purine pathway of pre-transplant liver biopsies are associated with graft function and survival after transplantation
Jin Xu, Post-doctoral Research Fellow (London, United Kingdom)

P-042  The inflammatory response in the context of tissue injury: roles of Tyro3, Axl, and Mer (TAM) receptors in liver ischemia/reperfusion injury
Jing Zhang (Los Angeles, Kosovo, Republic of)

P-043  Development of a split liver machine perfusion protocol to provide comparative controls in assessing therapeutic interventions
Joseph A Attard (Birmingham, United Kingdom)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-044</td>
<td><strong>Wip1 involves in hypothermic oxygenated machine perfusion (HOPE) improving transplantation outcome after donation after circulatory death</strong>&lt;br&gt;Junjun Jia (Hangzhou, China)</td>
<td></td>
</tr>
<tr>
<td>P-045</td>
<td><strong>Molecular injury phenotypes in human liver transplant biopsies: the INTERLIVER Study</strong>&lt;br&gt;Katelynn S. Madill-Thomsen (Edmonton, Canada)</td>
<td></td>
</tr>
<tr>
<td>P-046</td>
<td><strong>Molecular pathways associated with the Donor Risk Index</strong>&lt;br&gt;Bao-Li Loza (Philadelphia, United States)</td>
<td></td>
</tr>
<tr>
<td>P-047</td>
<td><strong>Hepatic miR-122 expression correlated with IL-28B genetic polymorphisms in patients with HCC who underwent LDLT</strong>&lt;br&gt;King-Wah Chiu, Associate Professor (Kaohsiung, Taiwan, Republic of China)</td>
<td></td>
</tr>
<tr>
<td>P-048</td>
<td><strong>Decreased expression of pigment epithelium-derived factor is associated with increased hepatic lipid accumulation</strong>&lt;br&gt;Kuang-Tzu Huang (Kaohsiung, Taiwan, Republic of China)</td>
<td></td>
</tr>
<tr>
<td>P-049</td>
<td><strong>Dasatinib synergizes SN38 prodrug-based nanoparticles to treat hepatocellular carcinoma</strong>&lt;br&gt;Li Xu (Hangzhou, China)</td>
<td></td>
</tr>
<tr>
<td>P-050</td>
<td><strong>Prognostic impact of peritumoral neutrophil infiltration on hepatocellular carcinoma recurrence following liver transplantation</strong>&lt;br&gt;Marc Najjar (New York, United States)</td>
<td></td>
</tr>
<tr>
<td>P-051</td>
<td><strong>Trans-differentiation of human infrapatellar fat pad derived stem cells generates functional hepatic-like tissue on gelatin-based 3D matrix (Liver-scaffold)</strong>&lt;br&gt;Mettu Reddy (Chennai, India)</td>
<td></td>
</tr>
<tr>
<td>P-052</td>
<td><strong>Therapeutic targeting of bile acid metabolism ameliorates liver ischemia/reperfusion injury</strong>&lt;br&gt;Ming Ni (Los Angeles, United States)</td>
<td></td>
</tr>
<tr>
<td>P-053</td>
<td><strong>Sirolimus attenuates calcineurin inhibitor induced epithelial-mesenchymal transition in hepatocellular carcinoma cell line</strong>&lt;br&gt;Ming Yuan Tan (Singapore, Singapore)</td>
<td></td>
</tr>
<tr>
<td>P-054</td>
<td><strong>Influence of curcumin on the expression of hepatic transporters in hepatic ischemia reperfusion injury</strong>&lt;br&gt;Min-Su Park (Seoul, Korea, Republic of)</td>
<td></td>
</tr>
<tr>
<td>P-055</td>
<td><strong>The recommendation diet for post-liver transplant patients in Vietnam: an initial experience from a single center</strong>&lt;br&gt;Nguyen Thu Ha (Ha Noi, Viet Nam)</td>
<td></td>
</tr>
<tr>
<td>P-056</td>
<td><strong>CircRNA 005186 aggravates mouse hepatic ischemia reperfusion injury via miRNA-124-3p/Epha2 pathway</strong>&lt;br&gt;Pengpeng Zhang, Dr. (Changsha, China)</td>
<td></td>
</tr>
<tr>
<td>P-057</td>
<td><strong>Comparison of cellulose nanofibrils with matrigel as a substrate for the differentiation of induced pluripotent stem cells (iPSCs) to hepatocytes</strong>&lt;br&gt;R Poorna M (Kochi, India)</td>
<td></td>
</tr>
<tr>
<td>P-058</td>
<td><strong>Hyperspectral imaging of human liver allografts</strong>&lt;br&gt;Robert Sucher (Leipzig, Germany)</td>
<td></td>
</tr>
<tr>
<td>P-059</td>
<td><strong>Cytotoxicity of FK506 through TRAIL pathways in human Jurkat T cells</strong>&lt;br&gt;Sang Young Chung, Professor (Gwangju, Korea, Republic of)</td>
<td></td>
</tr>
</tbody>
</table>
Scientific Programme

P-063  Liver-resident NK cells activity was maintained via the aryl hydrocarbon receptor (AhR)
Sato Koki (Hiroshima, Japan)

P-064  Development of novel scoring system for the prediction of viral-mediated hepatocellular carcinomas recurrence following liver transplantation
Secil Ak Aksoy (Bursa, Turkey)

P-065  IRF-1/JNK/Beclin1 pathway activates autophagy to aggravate hepatic ischemia-reperfusion injury in mice
Shi-Peng Li (Beijing, China)

P-066  Local layer by layer heparinization on in-vivo selective decellularized liver lobe scaffold. A further step towards in-vivo liver engineering
Uta Dahmen (Jena, Germany)

P-067  The normothermic machine perfusion (NMP) promoted liver regeneration is through the maintenance of cellular homeostasis
Wayel Jassem (London, United Kingdom)

P-068  Serum glycomics 7 days after liver transplantation relate to graft loss 3 months after liver transplantation independently of early allograft dysfunction
Xavier Verhelst, Dr. (Gent, Belgium)

P-069  Syndecan-4 promotes vascular beds formation in transplantable bionic liver via THBS1
Xiaoyi Hu (Hangzhou, China)

P-070  Prognostic value of circulating tumor cells counting after liver transplantation for hepatocellular carcinoma
Xin-Rong Yang (Shanghai, China)

P-071  The derivation and hepatocytes differentiation of hiEndoPCs from gastrointestinal epithelial cells using defined small molecules
XueTao Pei (Beijing, China)

P-072  Acetaldehyde drives mitochondrial depolarization-induced Type-2 mitophagy after acute ethanol treatment in mice
Zhi Zhong (Charleston, United States)

P-073  Brain death-mediated inflammatory liver injury is mediated by hepatocytes apoptosis through TRAIL
Zhong-Kun Huo (Zhengzhou City, China)

P-074  Aging aggravated liver ischemia and reperfusion injury by promoting Sting-mediated NLRP3 activation in macrophages
Zhuqing Rao (Nanjing, China)

Comorbidities, Infections and Complications

P-075  Severe anemia after liver transplantation: two cases report and review of the literature
Binshen Fu (Guangzhou, China)

P-076  Cardiometabolic risk profile of patients undergoing liver transplantation - a future challenge
Dinesh Jothimani, Dr (Chennai, India)

P-078  Long graft artery and arterial anomalies are risk factors for hepatic artery thrombosis after orthotopic liver transplantation
Martin Bailon-Cuadrado (Valladolid, Spain)
Scientific Programme

P-079  Hepatic artery thrombosis is a risk factors for anastomotic biliary stricture after orthotopic liver transplantation
Martin Bailon-Cuadrado (Valladolid, Spain)

P-080  Hepatic vein thrombosis after liver transplantation - a new technique for its correction
Murad Novruzbekov, Professor (Moscow, Russian Federation)

P-081  Liver transplantation and ischemic cardiopathy: feasibility and outcomes of pre-transplant coronary stenting
Paolo Magistri (Modena, Italy)

P-082  Sleeve gastrectomy compared with gastric bypass for morbidly obese liver transplant candidates
Rashikh Choudhury (Aurora, United States)

P-083  Readmission outcomes of bariatric surgery in liver transplant recipients
Rashikh Choudhury (Aurora, United States)

P-084  Inflammatory bowel disease in liver transplant patients: experience of our centre
Rocio González Grande, MD (Malaga, Spain)

P-085  Severe cytomegalovirus infection in a liver transplant patient refractory to conventional therapy: a case report
Rocio González Grande, MD (Malaga, Spain)

P-086  Mucormycosis adversely affects outcomes after living donor liver transplantation: a decade of experience from a large volume center
Swapnil Dhampalwar (Gurugram, India)

P-087  Pneumocystis jirovecii: An important differential with high mortality in pneumonia after Living Donor Liver Transplantation
Swapnil Dhampalwar (Gurugram, India)

P-088  Management of biliary complications after living donor liver transplantation in Acibadem Atakent Hospital
Tonguç Utku Yılmaz, Assoc. Dr. (İstanbul, Turkey)

P-089  Impact of pre-existing diabetes on outcomes following liver donor liver transplantation
Prashant Bhangui, MBBS, MS (Medanta, India)

P-090  The use of cryoprecipitate during liver transplantation and biliary complications - is there any connection?
Agnieszka Jóźwik (Warsaw, Poland)

P-091  Living donor liver transplantation for the patient with common variable immunodeficiency (CVID)
Akiko Nakazawa (Bunkyo-Ku, Tokyo, Japan)

P-092  Refractory acute antibody mediated rejection in liver transplant after desensitization of preformed donor specific antibody - validity of bortezomib and everolimus
Akira Maki (Kawagoe, Japan)

P-093  Pre-operative NT pro BNP can predict peri-operative morbidity and early outcomes in adult living donor liver transplantation recipients
Anupam Raj, Dr (New Delhi, India)
Scientific Programme

P-094  Sarcopenia is common in patients awaiting for liver transplantation and correlates with inflammatory status
Carlos Peteriro, MD (Zaragoza, Spain)

P-095  Diffusing capacity for carbon monoxide and perioperative renal outcomes in liver transplantation
Christopher King, Instructor (St Louis, United States)

P-096  Artificial intelligence may predict early post-operative sepsis in liver transplantation
Daniel Maluf, MD (Memphis, United States)

P-097  Multi-drug resistant Acinetobacter baumannii bacteremia after liver transplantation: a single center experience
Dong-Sik Kim, Professor (Seoul, Korea, Republic of)

P-098  Post liver transplant incisional hernia management
Ebru H. Ayvazoglu Soy (Ankara, Turkey)

P-099  Management of portal venous complications after liver transplant
Aydincan Akdur, MD (Ankara, Turkey)

P-100  Evaluation of latent tuberculosis infection in liver transplant recipients
Fereshteh Ghiasvand (Tehran, Iran, Islamic Republic of)

P-101  Unusual and unexpected complications after liver transplantation: pictorial review of multidisciplinary approach in graft saving procedures
Gabriele Catalano (Pisa, Italy)

P-102  Risk factors and impact of bacterial and viral infections in pediatric liver transplant recipients: single center experience
Hala Abdullatif (Cairo, Egypt)

P-104  Low incidence of major cardiac events in 1372 liver recipients: is aggressive screening for silent coronary disease justified?
John Klinck, MD (Cambridge, United Kingdom)

P-105  Anastomosis site stenosis after portal vein reconstruction through a choledocal vein in cavernous transformation of recipient portal vein: a case report
Ju Ik Moon, MD., Ph.D. (Daejeon, Korea, Republic of)

P-106  Renal safety of entecavir and tenofovir with hepatitis B immunoglobulin in liver transplant patients
Juhan Lee (Seoul, Korea, Republic of)

P-107  Co-infection of hepatitis B virus (HBV) and schistosomiasis: a report from Hunan province, central south of China
Junhui Li (Changsha, China)

P-108  Monotherapy with antivirals, after withdrawal of anti-HBV Immunoglobulin, as a treatment for the prevention of the recurrence of HBV infection in patients undergoing liver transplantation
Sonia Pascual, MD (Alicante, Spain)

P-109  Successful treatment of pulmonary cryptococcosis in a liver transplant recipient pre- and post-liver transplantation: case report and literature review
Li-Ying Sun, Ph.D MD (Beijing, China)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-110</td>
<td>Semaglutide is safe and effective in the treatment of post-transplantation diabetes mellitus in obese patients following liver transplantation</td>
<td>Maarten Tushuizen (Leiden, Netherlands)</td>
</tr>
<tr>
<td>P-111</td>
<td>Delta neutrophil index as a new mortality predictor after liver transplantation</td>
<td>Manki Ju (Seoul, Korea, Republic of)</td>
</tr>
<tr>
<td>P-113</td>
<td>Detrimental effect of macrosteatotic graft on renal function after liver transplantation</td>
<td>Marc Antoine Allard (Villejuif, France)</td>
</tr>
<tr>
<td>P-114</td>
<td>Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites in candidates for liver transplantation</td>
<td>Masahiro Ohira (Hiroshima, Japan)</td>
</tr>
<tr>
<td>P-115</td>
<td>Early postoperative mortality in liver transplant recipients in a high volume European transplant centre</td>
<td>Michał Grąt (Warsaw, Poland)</td>
</tr>
<tr>
<td>P-116</td>
<td>Therapeutic window for ribavirin therapy in transplant recipients with chronic hepatitis E virus infection</td>
<td>Midas B Mulder (Rotterdam, Netherlands)</td>
</tr>
<tr>
<td>P-117</td>
<td>Clinical features underlying persistent ascites after liver transplantation: portal vein thrombosis may enhance the risk of persistent ascites</td>
<td>Mohammad Taher (Tehran, Iran, Islamic Republic of)</td>
</tr>
<tr>
<td>P-118</td>
<td>Liver transplantation for acute on chronic liver failure</td>
<td>Naeem Goussous (Baltimore, United States)</td>
</tr>
<tr>
<td>P-119</td>
<td>Comparison of one-year morbidity following liver transplant for acute alcoholic hepatitis vs. alcoholic cirrhosis</td>
<td>Oya Andacoglu, Assistant Professor of Surgery (Bronx, United States)</td>
</tr>
<tr>
<td>P-120</td>
<td>Head-to-head comparison of intramuscular versus subcutaneous HBIG for maintenance HBV prophylaxis after liver transplantation</td>
<td>Paolo De Simone, MD (Pisa, Italy)</td>
</tr>
<tr>
<td>P-121</td>
<td>Predictors of positive blood culture and the outcome of blood culture positive sepsis in Indian liver transplant recipients</td>
<td>Rajesh Dey (New Delhi, India)</td>
</tr>
<tr>
<td>P-122</td>
<td>Diagnostic utility of serum beta-d-glucan for the detection of invasive fungal infections in liver transplant recipients</td>
<td>Samuel Tribich (London, United Kingdom)</td>
</tr>
<tr>
<td>P-123</td>
<td>Impact of Dengue infection in recipients of living donor liver transplantation: first case series from a large volume transplant center</td>
<td>Sanjiv Saigal, MD (Gurgaon, India)</td>
</tr>
<tr>
<td>P-124</td>
<td>Prevalence and clinical impact of preservation fluid infection in liver transplantation</td>
<td>Sara Cococcia (London, United Kingdom)</td>
</tr>
<tr>
<td>P-125</td>
<td>Long-term outcomes of preventing HBV recurrence with nucleotide and HBIG after liver transplantation for hepatitis B associated liver disease</td>
<td>Seong-Hwan Chang (Seoul, Korea, Republic of)</td>
</tr>
</tbody>
</table>
Scientific Programme

P-126 Tacrolimus-associated dilated cardiomyopathy after orthotopic liver transplant
Serdar Topaloglu, Professor (Trabzon, Turkey)

P-127 Neutrophil Lymphocyte Ratio can pre-empt development of clinical sepsis in patients post living donor liver transplant
Shashwat Sarin (New Delhi, India)

P-130 Early outcomes of JAK 2 inhibitor in the treatment of steroid refractory graft vs host disease on liver transplant recipients
Sunilkumar Kakadia (Little Rock, United States)

P-132 Portal venous thrombosis in transplanted cirrhotic patients at the Hospital Clinico Universidad de Chile
Víctor Nicolás Henríquez Auba, Dr. (Santiago, Chile)

P-134 Intestinal perforation after pediatric liver transplantation: a single-center experience
Xiaojie Chen (Beijing, China)

P-135 HLA antibody induced P-selectin mediated ASK1-JNK signal in endothelial cell apoptosis in AMR post liver transplant
Xueqin Meng (Hangzhou, China)

P-138 Bile microbiota: a new insight into liver transplant recipients with biliary complications
Ying Liu (Beijing, China)

P-139 Clinical analysis of the patients undergoing renal replacement therapy following living donor liver transplantation
Yongki Jeong (Seoul, Korea, Republic of)

P-140 Multiple bile duct and bleeding on cut edge of common bile duct are the risk factors for biliary complication after liver transplantation
YoungRok Choi (Sungnam-Si, Korea, Republic of)

P-141 Nursing experience for 42 recipients with immunosuppressant related diarrhea post liver transplantation
Yunxian Shang (Guangzhou, China)

P-142 Invasive fungal infection: incidence and predisposing factors: a report from a medium to high volume liver transplant center, Tehran, Iran
Zahra Ahmadi Nejad (Tehran, Iran, Islamic Republic of)

Donor Selection Criteria/Patient Selection/Organ Allocation

P-143 Pure laparoscopic versus open donor hepatectomy for adult living donor liver transplantation - a systematic review and meta-analysis
Abdul Rahman Hakeem (Chennai, India)

P-144 A single-center characterization of the living liver donor evaluation process
Ahmet Gurakar, MD (Baltimore, United States)

P-145 Clinical and liver allograft characteristics of HCV-positive donors
Behnam Saberi (New York, United States)

P-146 Clinical analysis of liver transplantation using aged liver grafts from donation after citizen’s death: a single center experience
Binsheng Fu (Guangzhou, China)
Scientific Programme

P-147  A sample of marginal cadaveric donor; to split or not to split?  
Cihan Karataş (Istanbul, Turkey)

P-148  Traveling for transplant: a comparison of singly listed, multiply listed, and non-citizen non-resident liver transplant candidates  
Hillary Braun (San Francisco, United States)

P-150  Variation in time of clinical profile and suitability criteria in liver donor after brain death (DBD)  
Marco Maria Pascale, MD (Rome, Italy)

P-151  Routine liver biopsy in assessing a potential donor - new perspectives on an old problem  
Murad Novruzbekov, Professor (Moscow, Russian Federation)

P-154  Salvaging discarded livers with normothermic machine perfusion: is it worth the cost?  
Reinier J de Vries (Boston, United States)

P-155  Ex-situ posterior graft segmentectomy for large-for-size syndrome in deceased donor liver transplantation in adults: a case report  
Sang Hoon Kim (Seoul, Korea, Republic of)

P-156  Changing indications for adult liver transplantation in Italy. Results from ECALITA: a nationwide registry study  
Tommaso Maria Manzia (Rome, Italy)

P-157  Successful usage of deceased donor liver allograft with grade IV Injury from blunt trauma  
Vivek Rajendran (New Delhi, India)

P-158  Incidence of hepatic artery thrombosis after liver transplantation in adults recipients using pediatric donors  
Allana Fortunato, MD (São Paulo, Brazil)

P-159  Renoportal anastomosis for primary allograft revascularization in liver transplant patients with extensive portal vein thrombosis: results of a recent single-center experience  
Amelia Hessheimer, MD (Barcelona, Spain)

P-160  Outcome of wait-listed recipients without the option for living donor liver transplantation at a newly established tertiary care liver transplant centre in Western India  
Amey Sonavane, DNB (Gastroenterology) (Gurugram, India)

P-161  Etiology specific liver transplant (LT) listings and determinants of waitlist mortality among patients with acute on chronic liver failure (ACLF) in the US.  
Ashwani Singal (Sioux Falls, United States)

P-162  Vascular reconstruction in portal vein thrombosis and its effect on survival after liver transplantation  
Bakhtiyar Kazymov (Moscow, Russian Federation)

P-163  Identification of serum exosomal miRNAs that predict hepatocellular carcinoma recurrence after liver transplantation  
Changbiao Li (Hangzhou, China)

P-164  Validation of the Donor Risk Index and the EuroTransplant Donor Risk Index on the China Liver Transplant Registry: a call for update  
Chuanhui Peng (Hangzhou, China)
P-165  Matching quality of liver graft to severity of recipient improves the survival benefit of liver transplantation  
Cyrille Feray, pr (Villejuif, France)

P-166  Active tumor on pre-transplant imaging impacts post-transplant recurrence rates  
David Victor, MD (Houston, United States)

P-167  Value of CTGF in assessment of liver graft with non-alcoholic fatty liver disease after brain death  
Dong-Jing Yang (Zhengzhou, China)

P-168  How far is the outcome of extended-criteria donor grafts from benchmark liver transplantation values in a single center with a low rate of deceased donation?  
Duilio Pagano, MD, PhD (Palermo, Italy)

P-169  Safety of marginal grafts in liver transplantation: a single center experience  
Hui Tang (Guangzhou, China)

P-170  Serotonin as predictive marker for graft quality in liver transplantation  
Isabelle Kersten (Vienna, Austria)

P-171  Safety of using elderly age grafts in liver transplantation for hepatocellular carcinoma patients: analysis of a national dataset  
Jie Zhou (Hong Kong, China)

P-172  Use of extended criteria donors in split liver transplantation- impact on paediatric patients  
Kanchan Motwani, Dr (Birmingham, United Kingdom)

P-173  Double eligibility criteria for transplant candidates with HCC: a decision-tree analysis approach for optimization without expansion  
Manuel Mendizabal (Pilar, Argentina)

P-174  The effect of elderly donor liver on the complications of recipients after liver transplantation: analysis and consideration on the prognosis of 148 patients  
Mengfan Yang (Hangzhou, China)

P-175  Outcomes of marginal grafts in cadaveric liver transplantation  
Pinar Tasar (Bursa, Turkey)

P-176  Deceased donors with hypernatremia does not impact early outcome in liver transplantation  
Qing Yang (Guangzhou, China)

P-177  Effect of pre-transplant sarcopenia on the estimation of the standard liver volume in living-donor liver transplant candidates  
Riccardo Pravisani (Udine, Italy)

P-178  Lowering meld, diminishing length of stay, and increasing liver transplant numbers comes through the generosity of others: declined HCV-NAT+ offers subsequently transplanted have excellent outcomes  
Richard Gilroy (Murray, United States)

P-179  Opinions of different religious on deceased organ donation  
Seyed Ali Malek-Hosseini (Shiraz, Iran, Islamic Republic of)

P-180  Selecting patients with decompensated cirrhosis and Acute-on-Chronic Liver Failure (ACLF) admitted to the Intensive care unit for liver transplantation  
Sophie-Caroline Sacleux (Villejuif, France)
Scientific Programme

P-182 Validation of the institutional criteria for marginal donors in deceased donor liver transplantation based on analyses of Japanese deceased donor score system
Yusuke Takemura (Tokyo, Japan)

Immunosuppression and Tolerance Induction

P-183 Small RNA extracellular vesicles isolated from liver perfusate provides assessment of organ quality and post-transplantation graft function
Amandeep Bajwa (Memphis, United States)

P-185 The effect of proteinuria and renal function impairment after switching mTOR inhibitor back to tacrolimus in liver transplantation patients
Sheng-Chih Kuo (Kaohsiung, Taiwan, Republic of China)

P-186 Tacrolimus accelerates CoCl2 - induced cytotoxicity via ER stress pathway in HepG2 cells
Soo Jin Na Choi (Gwangji, Korea, Republic of)

Living Donor Transplantation

P-187 Living donor Liver transplantation for 16 years old female with abernethy malformation and hepatic focal lesions
Amr Abdelaal (Cairo, Egypt)

P-188 Pattern of biliary complication in stentless(-) versus internal stented(+) biliary anastomosis post-living donor liver transplantation (pilot study)
Amr El Fouly (Cairo, Egypt)

P-191 Comparable outcomes in living donor and deceased donor liver transplantation for patients with high model for end-stage liver disease scores
Boram Lee (Gyeonggi-do, Korea, Republic of)

P-192 First case series of laparoscopic donor hepatectomy in Turkey
Cihan Karataş (Istanbul, Turkey)

P-193 Microsurgical biliary reconstruction in living donor liver transplantation: a 2-center experience with midterm outcomes
Deniz Balci, MD, PhD (Ankara, Turkey)

P-194 Liver transplantation: a changing trend of disease etiology in India
Dinesh Jothimani, Dr (Chennai, India)

P-195 Biliary reconstruction using high biliary radical is safe option for multiple graft bile duct in right lobe living donor liver transplantation
Eun-Kyoung Jwa (Seoul, Korea, Republic of)

P-196 Rare experience of emergency living donor liver transplantation due to mush room poisoning presenting with acute kidney injury and acute liver failure
Eun-Kyoung Jwa (Seoul, Korea, Republic of)

P-198 Portal vein thrombosis during liver transplantation: the risk of extra-anatomical portal vein reconstruction
Jinsoo Rhu (Seoul, Korea, Republic of)

P-199 Application of image-guidance using 2D illustrations and 3D modeling of donor anatomy during living donor hepatectomy
Jinsoo Rhu (Seoul, Korea, Republic of)
Scientific Programme

P-201  Portal flow modulations for large portosystemic shunt in liver transplantation: a single center experience
Ozgur Dandin, Assoc. Prof. (Giresun, Turkey)

P-202  Renoportal anastomosis for an extensive portal vein thrombosis with a large splenorenal shunt in living donor liver transplantation
Ozgur Dandin, Assoc. Prof. (Giresun, Turkey)

P-203  Offspring to parent living donor liver transplantation: an analysis of the A2ALL database
Rashikh Choudhury (Aurora, United States)

P-204  Parietal peritoneum as a novel substitute for middle hepatic vein reconstruction during living-donor liver transplantation
Suk Kyun Hong (Seoul, Korea, Republic of)

P-205  Outcomes of re-transplantation following live donor liver transplantation: the Toronto experience
Tommy Ivanics, MD (Toronto, Canada)

P-206  Outomes of liver transplantation among patients with autoimmune liver disease
Tonguç Utku Yılmaz, Assoc. Dr. (İstanbul, Turkey)

P-207  Small for size liver grafts can be used safely in living donor liver transplant with portal flow modulation using Octreotide infusion
Ahmed Zidan, Dr (Riyadh, Saudi Arabia)

P-208  The donor complications of live donor liver transplantation: single center experiences
Ahmet Kargi (İstanbul, Turkey)

P-209  ABO incompatible living donor liver transplantation at our institution
Akihiko Ichida (Tokyo, Japan)

P-210  Intraoperative blood glucose management with artificial pancreas in living donor liver transplantation
Akihiko Soyama (Nagasaki, Japan)

P-211  Living donor liver transplant (LDLT) for Alveolar Echinococcosis (AE): experience from a tertiary care centre
Arif Ali Khan, MBBs, MS, MCh (New Delhi, India)

P-212  Management for stricture and thrombosis of portal vein after living donor liver transplantation
Atsuyoshi Mita, Senior Assistant Professor (Matsumoto, Japan)

P-215  Early allograft dysfunction after live donor liver transplantation: It’s time to redefine?
Bramhadatta Pattnaik, Dr (New Delhi, India)

P-216  Staged ligation of large porto-systemic collaterals in living donor liver transplantation using a small-for-size graft
Chao-Long Chen, PhD (Kaohsiung, Taiwan, Republic of China)

P-217  Exploring perioperative time intervals in liver transplantation: cold ischaemia time being the most significant factor affecting patients’ clinical outcomes
Cheng Zhang, Dr. (Hangzhou, China)
Scientific Programme

P-218  Significance of HLA-mismatch or positive crossmatch on long-term survivals in living-related adult liver transplantation
Cheng-Maw Ho (Taipei, Taiwan, Republic of China)

P-219  Crucial V8 outflow reconstruction for a living donor after left lobe hepatectomy
Chih-Yi Chen (Kaohsiung, Taiwan, Republic of China)

P-221  Laparoscopic donor hepatectomy for posterior section graft
Choi Gyu-Seong (Seoul, Korea, Republic of)

P-222  Procalcitonin, a biomarker for diagnosing and differentiating infection from rejection among liver transplant recipients: a systematic review and meta-analysis
Ding-Yuan Wan (Chengdu, China)

P-224  The impact of non-directed anonymous live liver donors on the volume of children on the waitlist at a single pediatric liver transplant center
Whitney Jackson, MD (Aurora, United States)

P-225  Single-centre experience of adult LDLT in Yangon Specialty Hospital
Ei Ei Khine (Yangon, Myanmar)

P-226  Pure laparoscopic living donor right hepatectomy: single-center experience on 300 cases
Eui Soo Han (Seoul, Korea, Republic of)

P-227  Large Venous Outflow Reconstruction Using Artificial Graft As Common Orifice For Modified Right Liver Graft
Eun-Jeong Jang (Busan, Korea, Republic of)

P-229  Single-center retrospective analysis of thoracic epidural analgesia in donor hepatectomies - an experience of over a decade
Gupta Nikunj (Gurugram, India)

P-230  Novel technique for hepatic artery dissection in LDLT by using splenic artery
Hala Izzu, Fellow HPB/Liver Transplant (Gohbat, Pakistan)

P-231  Initial experience of the first 13 cases of purely laparoscopic living donor right hepatectomy
Ho Joong Choi (Seoul, Korea, Republic of)

P-232  Reconstruction of hepatic artery using gastroepiploic artery interposition graft for two small embedded hepatic arteries in left lobe live donor liver transplantation
Hyoung Tae Kim (Daegu, Korea, Republic of)

P-233  Efficacy and safety of weight reduction of the donor in hepatic steatosis for living donor liver transplantation
Je Ho Ryu (Yang-san, Korea, Republic of)

P-234  Demarcating the exact midplane of the liver using indocyanine green near-infrared fluorescence imaging during laparoscopic donor hepatectomy
Jeesun Kim (Seoul, Korea, Republic of)

P-235  A proposed predictive model for graft hyperperfusion syndrome after living donor liver transplantation using platelet count and portal vein flow as surrogates for portal pressure
Jeffrey Samuel Co, Dr. (Kaohsiung, Taiwan, Republic of China)

P-237  Lose weight to donate program: preliminary results of a program intended to optimize obese living donor liver candidates
John Rose (Charlottesville, United States)
Scientific Programme

P-238  De novo malignancy after LDLT  
Joo Seop Kim, prof (Seoul, Korea, Republic of)

P-239  Health-related quality of life after anonymous nondirected living liver donation: a multi-center, North American collaboration  
Juliet Emamaullee, MD, PhD (Los Angeles, United States)

P-240  5 years experience of right lobe living donor liver transplantation  
Kakhaber Kashibadze, MD Ph.D (Batumi, Georgia)

P-241  Advantages of extrahepatic glissonean approach in the donor operation in living donor liver transplantation  
Kazuya Hirukawa, Assistant professor (Tokyo, Japan)

P-242  Living donor liver transplantation using left lobe graft: the concept of functional graft size to maximize donor safety and recipient outcomes  
Koji Hashimoto (Cleveland, United States)

P-243  Migration of grafted polytetrafluoroethylene (PTFE) used for reconstruction of the middle hepatic vein into the stomach after living-donor liver transplantation  
Koo Jeong Kang (Daegu, Korea, Republic of)

P-245  Single surgeon’s initial experience with 100 cases of pure laparoscopic donor right heptectomy  
Kwang-Woong Lee (Seoul, Korea, Republic of)

P-246  Visceral adiposity is an independent risk factor for operative blood loss during adult living donor liver transplant: could preoperative rehabilitation and nutrition mitigate that risk?  
Mahmoud Macshut, MD (Kyoto, Japan)

P-247  Living donor liver transplantation within a family with factor XI deficiency: a unique case report  
Margaret Chong (Singapore, Singapore)

P-248  Overcoming hepatic artery thrombosis after living donor liver transplantations: an experience from the Asan Medical Center  
Min Jae Kim (Seoul, Korea, Republic of)

P-249  Liver transplantation in patients with portal vein thrombosis: a strategic road map throughout management  
Mohamed Sharshar (Kyoto, Japan)

P-250  Assessing the feasibility of universal application and outcomes of total laparoscopic donor heptectomy in a prospective study: an interim analysis  
Mohd Qaleem, Dr. (New Delhi, India)

P-251  Revisiting maximum surgical blood order schedule in living donor liver transplantation: are we ordering too much  
Monish Karunakaran (Gurugram, India)

P-252  Late onset acute cellular rejection and genetically unrelated donors are predictors of chronic rejection in living donor liver transplantation  
Narendra Singh Choudhary (Gurgaon, India)

P-253  The impact of donor BMI, metabolic, coagulation parameters on outcomes following Live Donor Liver Transplantation (LDLT)  
Nathalie H. Urrunaga (Baltimore, United States)
Scientific Programme

P-254  Splanchnic hemodynamics after right lobe living donor liver transplantation  
Oleg Kotenko (Kiev, Ukraine)

P-255  Living donor liver transplantation (LDLT) for patients with preformed donor-specific 
antibodies (DSA) - single institution experience  
Ryugen Takahashi (Tokyo, Japan)

P-256  Prospective comparison of robotic with open live donor right hepatectomy  
S T Binoj, Dr. (Ernakulam, India)

P-258  Hepatico-gastrostomy - a salvage option in difficult post-LDLT biliary strictures  
Sanjay Kumar Yadav, Associate Consultant (Gurgaon, India)

P-259  Long term outcome of chronic hepatitis B patient post living donor liver transplant and the 
impact of their donor hepatitis B immune status on it  
Sapana Verma, Fellow (New Delhi, India)

P-260  Anonymous living donor liver donation: establishing a protocol and understanding donors 
experience  
Sarah Shan (Charlottesville, United States)

P-261  How to control long term complications after liver transplantation  
Satoshi Omiya (Kobe, Japan)

P-262  How to protect against spontaneous graft migration after LDLT?  
Serdar Aslan (Istanbul, Turkey)

P-263  Convenient approach for recipient hepatectomy: left portal vein ligation for high hilar 
dissection  
Shams Zehri, Consultant (Ghambat, Pakistan)

P-264  The impact of albumin-bilirubin score on short- and long-term survival after living-donor 
liver transplantation: a retrospective study  
Shinichi So (Kobe, Japan)

P-266  Long-term outcomes of living and deceased donor liver transplantation for non-alcoholic 
steatohepatitis (NASH)  
Sindhuvalada Karnam Ravi Kiran (Toronto, Canada)

P-267  What women want - benefits of having a potential living liver donor in women  
Sindhuvalada Karnam Ravi Kiran (Toronto, Canada)

P-268  Unilateral laryngeal and palatal palsy due to ALF induced intra Cranial hypertension  
Sorabh Kapoor (Mumbai, India)

P-269  Incidence of acute kidney injury in living liver donor patients: a single center experience  
Süheyla Karadağ Erkoç (Ankara, Turkey)

P-271  Successful living donor liver transplantation from a donor with an extremely rare portal 
venous anomaly: “the circle of portal vein”  
Takako Fujii (Yamada) (Kobe, Japan)

P-272  Paired exchange living donor liver transplantation using compatible pairs- U.S. single 
center experience  
Tarunjeet Clair (San Antonio, United States)
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-276</td>
<td>Live donor liver transplantation for adult onset type II citrullinemia- a case report and review of literature</td>
<td>Venkatesh Sundararajan (New delhi, India)</td>
</tr>
<tr>
<td>P-277</td>
<td>Abdominal drainage after living donor liver transplantation (LDLT): a single centre experience</td>
<td>W.C. Dai, Honorary Clinical Associate Professor (Pokfulam, Hong Kong)</td>
</tr>
<tr>
<td>P-278</td>
<td>Surgical outcome of adult patients with preoperative portal vein thrombosis in living and deceased donor liver transplantation</td>
<td>Wong Hoi She, Associate consultant (Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>P-279</td>
<td>Pure laparoscopic donor right hepatectomy for large right hemi-liver graft: does it has a limit?</td>
<td>Worakitti Lapisatepun, Dr. (Seoul, Korea, Republic of)</td>
</tr>
<tr>
<td>P-281</td>
<td>Impact of living donor liver with steatosis and/or portal inflammation on short and long-term outcomes in pediatric liver transplantation (LT): Beijing experience</td>
<td>Yafei He (Beijing, China)</td>
</tr>
<tr>
<td>P-282</td>
<td>Cosmetic satisfaction and body image after adult living liver donor</td>
<td>Ya Lan Hsu (Changhua, Taiwan, Republic of China)</td>
</tr>
<tr>
<td>P-283</td>
<td>Challenge to living donor liver transplantation for babies under 3 months of age</td>
<td>Yasuharu Onishi (Shimotsuke, Japan)</td>
</tr>
<tr>
<td>P-284</td>
<td>A review of the role of the retroportal artery in the blood supply of the biliary tree: implications for liver transplant surgeons</td>
<td>Yasuhito Iwao, MD (London, United Kingdom)</td>
</tr>
<tr>
<td>P-285</td>
<td>Totally robotic living donor hepatectomy - duration and characteristics of graft parenchymal transection</td>
<td>Yee Lee Cheah, MD (Burlington, United States)</td>
</tr>
<tr>
<td>P-286</td>
<td>Clinical efficacy of laparoscopic and open Left Lateral Segment (LLS) resection in pediatric living donor liver transplantation (LDLT): a single-institution experience</td>
<td>Yi Luo (Shanghai, China)</td>
</tr>
<tr>
<td>P-288</td>
<td>Dual-graft adult living donor liver transplantation with both graft Duct-to-Duct biliary anastomosis: short-term and long-term outcomes</td>
<td>Yongkyu Chung (Seoul, Korea, Republic of)</td>
</tr>
<tr>
<td>P-289</td>
<td>The significance of portal flow of portocaval shunt during the anhepatic period to achieve good short term outcome in living donor liver transplantation</td>
<td>Yoshihiro Hirata (New Delhi, India)</td>
</tr>
<tr>
<td>P-291</td>
<td>No-touch en-bloc total hepatectomy technique in living-donor liver transplantation for hepatocellular carcinoma</td>
<td>Youngin Yoon (Seoul, Korea, Republic of)</td>
</tr>
<tr>
<td>P-292</td>
<td>Living donor liver transplantation with dual grafts - a case report</td>
<td>Yu Ju Hung (Changhua, Taiwan, Republic of China)</td>
</tr>
<tr>
<td>P-293</td>
<td>Psychometric properties of a common module for the quality of life scale of living organ donors (QLSLOD-CM V1.0) as based on liver donors</td>
<td>Yue-Xian Shi (Beijing, China)</td>
</tr>
</tbody>
</table>
Scientific Programme

P-294  Early infections after ABO-incompatible living donor liver transplantation
Yuichiro Mihara (Tokyo, Japan)

P-296  Clinical practices of cross-auxiliary domino donor liver transplantation
Zhijun Zhu (Beijing, China)

Anesthesia/Critical Care Medicine /Acute Liver Failure

P-297  Validity of post living donor liver transplant bilirubin, model of end-stage liver disease (MELD), delta bilirubin and delta MELD scores in predicting post-transplant outcomes
Anjana Ananth (Chennai, India)

P-298  Clinical implications of routine near infrared spectroscopy (NIRS) in live donor liver transplantation
Anjana Ananth (Chennai, India)

P-301  Fulminant hepatitis associated with inonotus obliquus boiled mushroom water in patient who had severe mitral valve stenosis and pulmonary hypertension: a case report
Sang Hoon Kim (Seoul, Korea, Republic of)

P-302  Establishing an independent coagulation laboratory for viscoelastic testing in liver transplantation
Uzung Yoon (Philadelphia, United States)

P-303  Postoperative biventricular failure after liver transplantation
Uzung Yoon (Philadelphia, United States)

P-304  Renal resistive index predicts acute kidney injury in patients undergoing living related liver transplantation - a prospective single centre study
Vijay Shankar (New Delhi, India)

P-305  Acute heart failure after living related liver transplantation: a case series
Vijay Shankar (New Delhi, India)

P-306  Supermassive blood transfusion in liver transplantation
Warangkana Lapisatepun (Chiang Mai, Thailand)

P-307  Total plasma exchange for management of early allograft dysfunction after living donor liver transplantation - an unmatched cohort study
Abdul Rahman Hakeem (Chennai, India)

P-308  Peri-operative management of severe hypoxemia secondary to hepatopulmonary syndrome: single center experience of four pediatric cases
Ambreen Sawant, Dr (Mumbai, India)

P-309  Immediate extubation in the operating room for pediatric liver transplants: one center's experience
Andrew Costandi, Clinical Associate Professor of Anesthes (Los Angeles, United States)

P-310  Comparison of thromboelastography (TEG) and rotational thromboelastometry (ROTEM) based protocols for coagulation management during orthotopic liver transplantation: a prospective randomized study
Anil Agarwal, Dr. (Noida, India)

P-311  Liver transplantation after liver crush injury: a case report
Annalisa Dolcet (London, United Kingdom)
Scientific Programme

P-312  Hand grip strength: a simple and effective way of prognostication for ICU readmission following living donor liver transplantation in adults
Ashish George (Chennai, India)

P-313  Early Use of methylene blue in severe septic shock during dissection phase of LDLT: a game changer
Ashish Malik, MD (New Delhi, India)

P-314  Evaluation of preoperative and postoperative s100β and NSE levels in liver transplantation and right lobe living-donor hepatectomy (prospective cohort study)
Bora Dinc, Assistant Professor (Antalya, Turkey)

P-315  Comparison of the prognostic scores of ACLF in predicting outcomes in a tertiary care centre in India
Deepak Sivalingam (Chennai, India)

P-316  Tacrolimus induced thrombotic thrombocytopenic purpura in pediatric live donor liver transplantation: two case reports
Donkena Navakanth (Hyderabad, India)

P-317  Case report: unanticipated challenges & management during donation after death orthotopic liver transplantation (DDLTx) requiring peripheral veno arterial extra corporeal membrane oxygenation (VA-ECMO)
Cynthia Williams (Aurora, United States)

P-318  Solid organ transplant recipients with pneumonia in intensive care unit: a single center study
Pinar Zeyneloglu (Ankara, Turkey)

P-320  Triggers for acute decompensation and acute on chronic liver failure in cirrhosis and their influence on outcome in a tertiary care centre in India
Giridharan Sridharan (Chennai, India)

P-321  Assessment of postoperative coagulation profile in patients undergoing living donor hepatectomy using rotational thromboelastometry
Hari Balakrishnan, Doctor (Chennai, India)

P-322  Anesthesia management of dual graft living donor liver transplantation; a case report
Hazel Nur Tezel (Ankara, Turkey)

P-323  Pre-operative supra-therapeutic midodrine in combination with octreotide infusion could be responsible for complete pulse-oximetry reading failure during the liver transplantation: a case review
Hyung Sun Choi, Assistant Professor (The Bronx, United States)

P-324  Outcomes following deceased and live donor liver transplantation for the indication of acute liver failure: a multicenter experience
Ilker Turan, Assoc. Prof. (Izmir, Turkey)

P-325  Treatment of hepatic encephalopathy by high flux hemodialysis: a case report
Jae Won Yang (Wonju, Korea, Republic of)

P-326  Impact of a surgical intensivist on the clinical outcome of liver transplant recipients
Jeeyoun Lim (Seoul, Korea, Republic of)
Scientific Programme

P-327  Intraoperative high-tidal-volume ventilation is independently associated with prolonged posttransplant ventilation in liver transplantation  
Jun Yang, Dr. (Yantai, China)

P-328  Pre-operative thromboelastography predicts transfusion during liver transplantation  
David Allison (Chicago, United States)

P-329  Outcomes in the use of extracorporeal membrane oxygenation as bridge to and through liver transplantation  
Michael Lin, Assistant Clinical Professor (Los Angeles, United States)

P-330  Implementation of automatic calculator for Portland protocol during liver transplantation  
Min Kyoung Cho (Seoul, Korea, Republic of)

P-331  Unmeasured ions in acid-base balance during liver transplantation - an observational case series  
Nandakumar Krishnaraju (New Delhi, India)

P-332  Effect of intraoperative dextrose infusion on perioperative hepatic functions in right living donor hepatectomy: a randomised controlled study  
Nidhi Sinha (New Delhi, India)

P-333  Trali (Transfusion related acute lung injury) prior to the Liver transplant - to proceed or not!!  
Dr. Nidhin, Specialist (MD,PDF) (Ernakulam, India)

P-334  Preemptive tracheoscopy in pulmonary infection after liver transplantation for ALF/ACLF  

P-335  Acute kidney injury within 7 days of liver transplantation affects renal function at day 30 after liver transplant  
Rachel Berkowitz (Ann Arbor, United States)

P-336  Severe congenital factor VII deficiency and normal ROTEM analysis in a hepatectomy  
Richard Yeom, Resident Physician (Philadelphia, United States)

P-337  Perioperative ECMO support - the King’s College experience: ECMO as a bridge to emergency liver transplantation, for intra-op salvage, and post liver transplantation  
Sameer Patel (London, United Kingdom)

P-338  Epidemiological and prognostic characteristics of severe acute hepatitis in a liver transplat unit  
Sonia Pascual, MD (Alicante, Spain)

P-339  Evaluation of safety and efficacy of peripherally inserted central venous catheters(PICC) for short and medium term postoperative venous access in liver transplant recipients  
Selvakumar Malleeswaran, Consultant Anesthetist and Intensivist (Chennai, India)

P-340  Does a change from normal saline to balanced crystalloid during liver transplant influence postoperative renal function?  
Shaun Yockelson, Assistant Professor (New Orleans, United States)

P-341  Congenital heart disease (atrial septal defects) and liver transplantation: is it safe??  
Shrijit Nair, Dr (London, United Kingdom)

P-342  The utility of Transcranial Doppler in the management of intracranial hypertension in acute liver failure patients  
Sivanesan Sivajothi (Chennai, India)
Scientific Programme

P-343 Early extubation of liver transplant recipients: a quality improvement project
Sneha Rao, Dr (Baltimore, United States)

P-344 Successful management of a liver transplant patient with significant hepatopulmonary syndrome
Sook Muay Tay, Doctor (Singapore, Singapore)

P-345 Liver transplantation under veno-venous extracorporeal membrane oxygenation support in patients with severe acute respiratory failure
Soon Ji Park (Yangsan, Korea, Republic of)

P-346 Successful management of liver transplant in a patient with severe hepatopulmonary syndrome
Steffi Kang Ting Chan (Singapore, Singapore)

P-347 Extracorporeal membrane oxygenation as a bridge to liver transplantation for acute respiratory distress syndrome - induced life threatening hypoxemia aggravated by end-stage liver disease
Tae Beom Lee (Yansan-si, Korea, Republic of)

P-348 Management of a case of Hereditary Hemorrhagic Telangiectasia involving the liver causing high output cardiac failure as an indication for liver transplantation
Vivienne Hannon (San Francisco, United States)

P-349 Liver transplantation of a patient with extreme thrombocytopenia: a case report
Yena Oh (Seoul, Korea, Republic of)

P-350 Transfusion strategies for ABO incompatible living donor liver transplantation our first experience
Yingke He, Dr. (Singapore, Singapore)

P-351 Comparison of prognostic scores to predict short-term mortality after liver transplantation in HBV-related acute-on-chronic liver failure patients
Yingzi Ming (Changsha, China)

P-352 Prolonged liver graft preservation: comparison between static cold storage and hypothermic oxygenated machine perfusion
Daniele Dondossola (Milan, Italy)

P-353 Biological characterization of grafts derived from brain and cardiac death donors during oxygenated-hypothermic machine perfusion
Daniele Dondossola (Milan, Italy)

P-354 Temporal trends in utilization and outcomes of DCD livers for liver transplantation in the United States
Kyle Jackson (Baltimore, United States)

P-355 Successful use of injured DCD liver grafts
Paolo Magistri (Modena, Italy)

P-356 Long term outcomes following uncontrolled and controlled donation after cardiac death liver transplantation in the United States
Rashikh Choudhury (Aurora, United States)
Scientific Programme

P-357  Uncontrolled DCD vs DBD liver transplantation in the United States: Is it safe to push the envelope?
Rashikh Choudhury (Aurora, United States)

P-358  Early liver transplant outcomes after normothermic machine perfusion
Satheesh Iype (London, United Kingdom)

P-359  Normothermic machine perfusion (NMP) of paediatric DCD liver and successful transplantation to adult recipient
Satheesh Iype (London, United Kingdom)

P-361  First Russian experience of liver transplantation from donor with out-of-hospital irreversible cardiac arrest
Alexander Zakharenko, MD (Saint-Petersburg, Russian Federation)

P-362  Reuse of liver allograft from a brain-dead liver transplant recipient: a case report
Charles Panackel (Kochi, India)

P-363  Outcomes of donation after circulatory death liver allografts from donors 70 years or older: a Nationwide National Health Service Blood & Transplant (NHSBT UK) analysis
Emmanouil Giorgakis, Assistant Professor (Little Rock, United States)

P-364  The first series of normothermic machine perfusion in India - the way ahead
G V Premkumar, HOD (Secunderabad, India)

P-365  Development of a simplified rat model of normothermic machine perfusion (NMP) followed by orthotopic liver transplantation: a new tool for detailed assessment?
Hidetaka Miyauchi (Kyoto, Japan)

P-366  Liver donor boarding pass for using the machine perfusion
Irene Scalera (Naples, Italy)

P-367  Comparing normothermic mechanical perfusion with different portal perfusion pressures on rat livers from cardiac dead donors
Ji-Hua Shi (Zhengzhou, China)

P-368  Good posttransplant outcome using donors after cardiac death (DCD) when applying strict selection criteria
Victoria Aguilera Sancho-Tello (Valencia, Spain)

P-369  Release of transaminases (AST/ALT) during liver flushing in a prospective liver transplant clinical study: the washout phenomenon and implications for machine perfusion preservation studies
Paulo Martins, MD, PhD (Worcester, United States)

P-370  Ex situ normothermic machine perfusion as salvage for liver grafts following unsuccessful in situ normothermic regional perfusion
Rohit Gaurav (Cambridge, United Kingdom)

P-371  Single-center experience of extracorporeal membrane oxygenation assisted cardiac death organ donation for renal transplantation
Yuling An (Guangzhou, China)
Scientific Programme

P-372 HCC associated with benign or malignant portal vein thrombosis: the limits of in-adherence to BCLC-staging in the setting of living donor liver transplant
Amr El Fouly (Cairo, Egypt)

P-379 Living donor liver transplantation for advanced hepatocellular carcinoma with portal vein tumor thrombosis after concurrent chemoradiation therapy
Jae Geun Lee (Seoul, Korea, Republic of)

P-380 Liver transplantation for non-resectable colo-rectal liver metastasis
Jean Botha, Professor (Johannesburg, South Africa)

P-381 The application of electron microscope examination in evaluation of donor liver quality in liver transplantation
Maogen Chen (Guangzhou, China)

P-382 Liver transplant for alcoholic cirrhosis and de novo malignancies
Marco Maria Pascale, MD (Rome, Italy)

P-384 Role of hepatologists in management of hepatocellular carcinoma in the new era of transplant oncology
Tomohiro Tanaka, MD, PhD (Iowa City, United States)

P-385 Outcomes of living donor liver transplantation for hepatocellular carcinoma and usefulness of the risk estimation of tumor recurrence after transplant (RECREATE) score
Vivek Rajendran (New Delhi, India)

P-386 Liver transplantation for primary sclerosing cholangitis
Aydincan Akdur, MD (Ankara, Turkey)

P-387 Aminoacylase 1 is a promising biomarker for the diagnosis of hepatocellular carcinoma
Binhua Pan (Hangzhou, China)

P-388 Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation
Birkan Bozkurt (Istanbul, Turkey)

P-389 Whole-exome sequencing identifies distinct somatic alterations in intrahepatic and hilar cholangiocarcinoma
Chang Xian Li (Nanjing, China)

P-390 Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma
Chia En Hsieh (Changhua, Taiwan, Republic of China)

P-391 The matching status between donor and recipient hepatitis B seroepidemiology makes a difference in liver transplantation for hepatocellular carcinoma
Di Lu (Hangzhou, China)

P-392 Pathologic complete response to chemoembolization improves survival outcome after curative surgery for hepatocellular carcinoma
Dong Goo Kim, M.D. (Seoul, Korea, Republic of)

P-393 Incidental hepatocellular carcinoma/cholangiocarcinoma and intrahepatic cholangiocarcinoma: a single-liver transplant center experience
Ender Anılır (İstanbul, Turkey)
### Scientific Programme

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-394</td>
<td>Can we prevent bleeding or seeding after biopsy for HCC in cirrhotic liver patient?</td>
<td>Fatih Boyvat, MD, PhD (Ankara, Turkey)</td>
</tr>
<tr>
<td>P-395</td>
<td>Metroticket 2.0 and AFP score have similar performance to predict post-LT outcomes: results of a multinational multicentre cohort study</td>
<td>Helena Degroote (Ghent, Belgium)</td>
</tr>
<tr>
<td>P-396</td>
<td>Two case reports of successful immunotherapy with PD-1 inhibitor based on allograft PD-L1 expression in patients with recurrent of hepatocellular carcinoma after liver transplantation</td>
<td>Guo-Ying Wang (Guangzhou, China)</td>
</tr>
<tr>
<td>P-397</td>
<td>Interference of miR-107 with Atg12 is inhibited by HULC to promote metastasis of hepatocellular carcinoma</td>
<td>Hai-Ming Zhang (Beijing, China)</td>
</tr>
<tr>
<td>P-398</td>
<td>Living donor liver transplantation for hepatocellular carcinoma: risk factors of recurrence and mortality in patients beyond Milan criteria</td>
<td>Hsin Rou Liang (Changhua, Taiwan, Republic of China)</td>
</tr>
<tr>
<td>P-399</td>
<td>Clinical impact of the treatment modality on small, solitary, recurrent intrahepatic hepatocellular carcinoma after primary liver resection</td>
<td>Hyo-Sin Kim, MD (Gwangju, Korea, Republic of)</td>
</tr>
<tr>
<td>P-400</td>
<td>Upregulation of Anillin actin binding protein promotes resistance of liver cancer cells to Wee1 inhibition</td>
<td>Jian Chen (Hangzhou, China)</td>
</tr>
<tr>
<td>P-401</td>
<td>Salvage liver transplantation versus re-resection for recurred HCC after hepatectomy in patients with Child-A liver cirrhosis</td>
<td>Suhyeon Ha (Seoul, Korea, Republic of)</td>
</tr>
<tr>
<td>P-402</td>
<td>CX3CL1/CX3CR1-dependent regulatory macrophage infiltration promotes tumor recurrence after liver transplantation for intrahepatic cholangiocarcinoma</td>
<td>Jiye Zhu (Hong Kong, China)</td>
</tr>
<tr>
<td>P-403</td>
<td>Refining postoperative HCC recurrence risk model for LT centres from regions of severe organ shortage: a multicenter study</td>
<td>Ka Wing Ma (Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>P-404</td>
<td>ROR1 promotes tumor progression via inhibiting autophagy and inducing clathrin-mediated endocytosis in cholangiocarcinoma</td>
<td>Long Zhao (Hangzhou, China)</td>
</tr>
<tr>
<td>P-405</td>
<td>Results of liver transplantation in the treatment of hepatic alveolar echinococcosis</td>
<td>Marcin Kotulski, PhD (Warsaw, Poland)</td>
</tr>
<tr>
<td>P-408</td>
<td>The clinical analysis of patients with hepatocellular carcinoma and branched portal vein tumor thrombus after liver transplantation</td>
<td>Meng Sha (Shanghai, China)</td>
</tr>
<tr>
<td>P-409</td>
<td>Incidence and prognostic impact of cancer after liver transplantation</td>
<td>Mikel Gastaca (Bilbao, Spain)</td>
</tr>
<tr>
<td>P-410</td>
<td>Successful liver transplantation following complete remission of advanced stage hepatocellular carcinoma after anti-PD 1 antibody therapy: a case report</td>
<td>Ming-Che Lee, Professor of Surgery (Hualien, Taiwan, Republic of China)</td>
</tr>
</tbody>
</table>
Scientific Programme

P-411 Liver transplantation for hepatocellular carcinoma beyond Milan criteria
Oleg Olisov (Moscow, Russian Federation)

P-412 Anillin actin binding protein contributes proliferation of cancer cells by promoting cytokinesis
Penghong Song (Hangzhou, China)

P-414 The impact of geographical area in HBV patients with hepatocellular cancer undergoing liver transplantation
Quirino Lai (Brussels, Belgium)

P-415 Liver transplantation for Epithelioid Hemangioendothelioma (EHE) - short and long-term outcomes from 30 years' experience
Rajendran Vellaisamy (London, United Kingdom)

P-416 Early versus late hepatocellular carcinoma (HCC) recurrence after liver transplantation for HCC: patterns and long-term outcome
Faouzi Saliba (Villejuif, France)

P-417 Validation of RETREAT score for prognosis of hepatocellular carcinoma post-liver transplant in a UK centre
Shruthi H S Reddy, Dr (London, United Kingdom)

P-418 TSC1/2 mutations - a unique type of mutation suitable for liver transplantation of hepatocellular carcinoma
Shu Hong Yi, professor (Guangzhou, China)

P-419 Examination and countermeasures for de novo malignant tumor after liver transplantation at Hiroshima University
Shuji Akimoto (Hiroshima, Japan)

P-420 Role of hepatocellular carcinoma therapy for patients in the waiting list for liver transplant
Sonia Pascual, MD (Alicante, Spain)

P-421 Number of locoregional therapies and tumor size predict recurrence risk and outcomes post liver transplant
Sudha Kodali, MD (Houston, United States)

P-422 Two stage living donor liver transplantation for patients with non-resectable liver metastases from colorectal carcinoma
Utz Settmacher, Prof. Dr. (Jena, Germany)

P-423 Liver transplantation for larger hepatocellular carcinoma: Malatya experience
Volkan Ince, Assistant professor (Malatya, Turkey)

P-424 De novo malignancy after liver transplantation: experience of a single institution
Wen-Tsan Chang, Assistant professor (Kaohsiung, Taiwan, Republic of China)

P-425 Challenges in listing patients with primary sclerosing cholangitis - how confident can we be in ruling out concomitant cholangiocarcinoma. The Irish National experience
William Duggan (Dublin 4, Ireland)

P-426 Homocysteine: a novel prognostic biomarker in liver transplantation for alpha-fetoprotein-negative hepatocellular carcinoma
Win Yen Tan (Hangzhou, China)
Scientific Programme

P-427  PSMC2 regulates cell proliferation, apoptosis, cell cycle and predicts poor prognosis in human hepatocellular carcinoma  
Xiaofeng Wu (Nanjing, China)

P-428  Mir-98a/ADRB2 promotes hepatocellular carcinoma recurrence and metastasis via fostering mapk/erk pathway  
Xuanyu Zhang (Hangzhou, China)

P-430  Multiomics profiling reveals the crosstalk between sarcopenia and hepatocellular carcinoma in liver transplantation  
Zuyuan Lin (Hangzhou, China)

Pediatrics

P-431  Overall experience in pediatric living donor liver transplantation (single center experience)  
Amr Abdelaal (Cairo, Egypt)

P-432  Excellent 10-year outcome after pediatric living donor liver transplantation  
Chih-Che Lin, Associate Professor (Kaohsing, Taiwan, Republic of China)

P-435  ABO incompatible liver transplantation in children with acute liver failure  
Jean Botha, Professor (Johannesburg, South Africa)

P-437  Flow dynamics predict PVT in pediatric LDLT  
SaurabhSinghal, Dr. (New Delhi, India)

P-438  Incomplete resolution of portal hypertension drives chylos ascites in pediatric LDLT recipients  
SaurabhSinghal, Dr. (New Delhi, India)

P-439  Uncovering the pathogenesis of extrahepatic biliary atresia: link to autoimmune etiology  
SaurabhSinghal, Dr. (New Delhi, India)

P-440  Risk factors for hepatic artery complications in pediatric liver transplantation  
Suk Kyun Hong (Seoul, Korea, Republic of)

P-441  Outcome of pediatric liver transplantation and risk factors affecting overall survival: using two Korean National Registry Data  
Suk Kyun Hong (Seoul, Korea, Republic of)

P-442  Hybrid procedure: intra-operative ERCP guided controlled dilatation of the strictured hepatico-jejunostomy in pediatric liver transplant recipients  
ArunkumarVenuthurimilli (New Delhi, India)

P-443  Surgical management of duct-to-duct anastomotic strictures in pediatric liver transplantation  
CahitYılmaz, M.D. (Izmir, Turkey)

P-444  Split liver transplantation is associated with favorable outcomes both in children and adults recipients  
CarolineLemoine (Chicago, United States)

P-445  Effect of preoperative blood stream infection on outcomes in pediatric liver transplant recipients  
ChiakiBaba (Tokyo, Japan)
<table>
<thead>
<tr>
<th>P-446</th>
<th>Impact of split liver and segmental graft use on waitlist time: does it affect pediatric liver transplant outcomes?</th>
<th>Fidel Lopez-Verdugo, MD (Salt Lake City, United States)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-447</td>
<td>Splenic artery steal syndrome after pediatric liver transplantation: a case report</td>
<td>Jairo Eduardo Rivera Baquero (Bogotá, Colombia)</td>
</tr>
<tr>
<td>P-448</td>
<td>Characteristic of patients with biliary atresia who underwent liver transplantation within 90 days after Kasai's procedure</td>
<td>Keita Shimata (Kumamoto, Japan)</td>
</tr>
<tr>
<td>P-449</td>
<td>Portal vein reconstruction with PTFE graft interposition: a navel rescue option for recurrent portal vein thrombosis in pediatric liver transplantation</td>
<td>Madhusudhan Chinthakindi (Hyderabad, India)</td>
</tr>
<tr>
<td>P-450</td>
<td>Arterial conduits using Cattell-Braasch maneuver for hepatic artery reconstruction in pediatric liver transplantation</td>
<td>Marek Stefanowicz (Warszawa, Poland)</td>
</tr>
<tr>
<td>P-451</td>
<td>Successful liver transplantation for Alagille syndrome. Single center experience</td>
<td>Masoud Dehghani (Shiraz, Iran, Islamic Republic of)</td>
</tr>
<tr>
<td>P-453</td>
<td>Hepatic venous outflow reconstruction for pediatric live donor liver transplantation</td>
<td>Rasim Farajov, MD (Izmir, Turkey)</td>
</tr>
<tr>
<td>P-454</td>
<td>Pediatric histiocytic disorders that required liver transplantation and splenectomy</td>
<td>Rie Irie (Tokyo, Japan)</td>
</tr>
<tr>
<td>P-455</td>
<td>Outcome of portal vein reconstruction using branch patch anastomosis in pediatric living related liver transplant recipients weighing less than 10 kg</td>
<td>Roshan Ghimire, Fellow (New Delhi, India)</td>
</tr>
<tr>
<td>P-456</td>
<td>Efficacy of living donor liver transplantation for patients with methylmalonic acidemia</td>
<td>Seo Hee Kim (Seoul, Korea, Republic of)</td>
</tr>
<tr>
<td>P-457</td>
<td>Pediatric liver transplantation outcome; Single center experiences</td>
<td>Şerafettin Yazar (İstanbul, Turkey)</td>
</tr>
<tr>
<td>P-458</td>
<td>Liver transplantation in pediatric hepatic angiosarcoma: a case report</td>
<td>Sifat Khan (Birmingham, United Kingdom)</td>
</tr>
<tr>
<td>P-459</td>
<td>Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation: a single center experience</td>
<td>Tian Qin (Shanghai, China)</td>
</tr>
<tr>
<td>P-460</td>
<td>Overcoming economic barriers to establish a pediatric liver transplantation program in a developing country</td>
<td>Vikram Raut, Associate Professor (Mumbai, India)</td>
</tr>
<tr>
<td>P-461</td>
<td>Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation</td>
<td>Wei Gao, Prof. (Tianjin, China)</td>
</tr>
<tr>
<td>P-462</td>
<td>Methylmalonic and propionic acidemia among hospitalized pediatric patients: a Nationwide report</td>
<td>Yizhou Jiang (Beijing, China)</td>
</tr>
</tbody>
</table>
Scientific Programme

P-463  Bilioenteric reconstruction techniques in pediatric live donor liver transplantation  
Zaza Iakobadze, M.D. (İzmir, Turkey)  
Radiology/Interventional Radiology/Molecular Imaging

P-464  Accuracy of the Liver Imaging Reporting and Data System version 2017 for hepatocellular carcinoma in liver transplanted patients  
Faeze Salahshour, assistant professor (Tehran, Iran, Islamic Republic of)

P-465  Clinical usefulness of MRI pancreatobiliary fistula for diagnosis of biliary leakage after living donor liver transplantation  
Kwangpyo Hong (Seoul, Korea, Republic of)

P-466  Long-term outcome of the Rendezvous technique in patients with severe biliary anastomotic stricture that cannot cannulate after liver transplantation  
Kyeong Sik Kim (Seoul, Korea, Republic of)

P-467  Urgent salvage endovascular treatment of early arterial flow disorders after liver transplantation  
Yan Moysyuk, Prof. (Moscow, Russian Federation)

P-468  Normal Range of hepatic hemodynamic for complication-free children with living related donor liver transplantation (LDLT) at early postoperative period: a retrospective study  
Ying Tang, doctor (Tianjin, China)

Short and Long-term Patient and Allograft Outcomes/Recurrence of Benign Diseases

P-469  Benefit of anti-hepatitis B immunoglobulin (HBIG) monotherapy compared to HBIG combined with Entecavir in long term renal function  
Jae Geun Lee (Seoul, Korea, Republic of)

P-471  Recurrence and the survival analysis of liver transplanted hepatocellular carcinoma patients  
Ebru H. Ayvazoglu Soy (Ankara, Turkey)

P-472  Evaluation of immunological status of recurrent primary biliary cholangitis and primary sclerosing cholangitis after liver transplantation  
Tanaka Asuka (Hiroshima, Japan)

P-473  Hepatitis C positive donor liver transplantation to hepatitis C seronegative recipients  
Ahmet Gurakar, MD (Baltimore, United States)

P-474  Hepatocyte growth factor (HGF) prevents the apoptotic and anti-angiogenic effect of hypercholesterolemia on hepatocytes in liver allografts  
B. Handan Ozdemir (Ankara, Turkey)

P-475  Hepatitis D recipients have similar post-liver transplant survival compared to HBV  
Behnam Saberi (New York, United States)

P-477  Is de-novo non-alcoholic fatty liver disease (NAFLD) post liver transplantation a problem affecting patient long-term survival?  
Gloria Sanchez Antolin, MD, PhD (Valladolid, Spain)

P-478  Efficacy and safety of self-expandable metal stents in the management of biliary complications after liver transplantation  
Gloria Sanchez Antolin, MD, PhD (Valladolid, Spain)
**Scientific Programme**

| P-479 | Opioid use prior to liver transplant is associated with increased risk of death after transplant |
|       | Hillary Braun (San Francisco, United States) |
| P-481 | Temporal trends in the incidence and impact of biliary complications following liver transplantation |
|       | Kyle Jackson (Baltimore, United States) |
| P-482 | Liver transplantation and portal vein thrombosis: University of Modena experience |
|       | Paolo Magistri (Modena, Italy) |
| P-484 | Bile microbiology and antibiotic susceptibility in liver transplant recipients versus non-transplant population |
|       | Suk-Won Suh (Seoul, Korea, Republic of) |
| P-485 | Remodulation of early allograft dysfunction estimation, the role of graft weight on early allograft success: a multicentre cohort Study |
|       | Tommaso Maria Manzia (Rome, Italy) |
| P-486 | Survival after liver transplantation; an international comparison between the United States and the United Kingdom and Ireland |
|       | Tommy Ivanics, MD (Toronto, Canada) |
| P-488 | Impact of the share 35 policy on the perioperative management in liver transplantation |
|       | Warangkana Lapisatepun (Chiang Mai, Thailand) |
| P-489 | Long-term outcomes of liver transplants for NASH from a large single institutional cohort |
|       | Aamir Nawaz, Mr (London, United Kingdom) |
| P-490 | Hepatic steatosis and liver fat contents measured by controlled attenuation parameter in liver transplant recipients is associated with serum adipokines and insulin resistance |
|       | Ahad Eshraghian (Shiraz, Iran, Islamic Republic of) |
| P-491 | An analysis of the outcomes of patients with liver retransplantation - a single center experience |
|       | Aihua Yao (Nanjing, China) |
| P-492 | Liver transplantation short and long term survival: a low-middle income country single center report of 1000 cases |
|       | Ali Jafarian (Tehran, Iran, Islamic Republic of) |
| P-493 | Reports from one of the largest liver transplantation centers in the world, the Shiraz liver transplantation registry (SLTR): experiences and lessons learned |
|       | Ali Malek-Hosseini (Shiraz, Iran, Islamic Republic of) |
| P-494 | Outcomes of hepatitis B immunoglobulin in hepatitis B transplantation: a UK and Ireland perspective |
|       | Alison Orr (London, United Kingdom) |
| P-496 | PNPLA3 and NOTCH3 gene polymorphisms and their impact on acute cellular rejection after liver transplantation - a single centre pilot study |
|       | Anna Mrzljak (Zagreb, Croatia) |
| P-497 | Non alcoholic fatty liver disease (NAFLD) after liver transplantation: prognosis, risk factors and role of dietary habits and lifestyle |
|       | Borao Cristina, MD (Zaragoza, Spain) |
Scientific Programme

P-498  Non-alcoholic steatohepatitis  
Can Karaca (Izmir, Turkey)

P-499  Impact of pre-liver transplant opioid use on post-liver transplant patient outcomes  
Caroline Josephine Simon (Burlington, United States)

P-500  Muscle loss in patients with NASH cirrhosis receiving liver transplantation: comparison with non-transplant cohorts and outcomes  
Chandra Bhati, Assistant Professor (Richmond, United States)

P-501  Long-term liver fibrosis and outcomes in HCV-infected solid organ transplant recipients after DAAs-induced viral eradication  
Chiara Manuli (Padova, Italy)

P-502  Post-transplantation outcomes after deceased donor liver transplantation: an international comparison between the United States and the United Kingdom and Ireland  
David Wallace, Clinical Research Fellow (London, United Kingdom)

P-503  Deterioration of functional status on the waiting-list is associated with increased post-transplant mortality  
Dmitri Bezinover, MD (Hershey, United States)

P-504  Outcomes of liver transplantation of urgently listed patients in Australia and New Zealand: The impact of donor risk index  
Eunice Lee (Melbourne, Australia)

P-505  Factors associated with prolonged recipient hepatectomy time during liver transplantation: a single center experience  
Fabio Ausania (Barcelona, Spain)

P-506  Outcomes of Porto-Pulmonary Hypertension (PPH) in the setting of liver transplantation  
Geoffrey McCaughan, MD, PhD (Sydney, Australia)

P-507  Active screening of urine ethylglucuronide to confirm alcohol abstinence prior to waitlisting for liver transplantation  
Gonzalo P. Rodriguez-Laiz, Dr. (Alicante, Spain)

P-508  The compromised therapeutic value of liver transplantation in a pediatric patient with ethylmalonic encephalopathy  
Guang-Peng Zhou, M.D. (Beijing, China)

P-509  The impact of recipients age on survival following liver transplantation  
Habibollah Dashhti, Dr. (Tehran, Iran, Islamic Republic of)

P-510  The effect of diabetes mellitus on long-term outcomes in adult liver transplantation  
Hiroaki Yamane (Hiroshima, Japan)

P-511  Adult split liver transplants increased after implementation of a pediatric liver transplant program  
J Michael Cullen (Charlottesville, United States)

P-512  Risk factors for early mortality after adult deceased donor liver transplantation  
Jalil Makarem, Associate Professor (Tehran, Iran, Islamic Republic of)

P-513  New start small single center experience: our first 5 years liver transplantation  
Jeong Sung Yub (Sungnam KyungGi-do, Korea, Republic of)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-514</td>
<td>Are liver transplant (LT) indications and receptor profile changing in the recent years? Results of a retrospective and unicentric study</td>
<td>Julia Herreras (Valencia, Spain)</td>
</tr>
<tr>
<td>P-515</td>
<td>Indication of liver transplantation in the treatment of newly categorized acute-on-chronic liver failure in Japan</td>
<td>Kaori Kuramitsu, MD, PhD (Kobe, Japan)</td>
</tr>
<tr>
<td>P-516</td>
<td>Hepatic Artery (HA) reconstruction on back table in deceased-donor liver transplantation surgery. 10-year experience of a single center</td>
<td>Halit Ziya Dundar, MD (Bursa, Turkey)</td>
</tr>
<tr>
<td>P-517</td>
<td>Combined heart-liver transplantation - first series in cooperating high volume transplant centers</td>
<td>Krzysztof Zieniewicz, MD, PhD (Warsaw, Poland)</td>
</tr>
<tr>
<td>P-518</td>
<td>Internet platform TRANSPLANT.NET for a remote monitoring of solid-organ transplant recipients</td>
<td>Yan Moysyuk, Prof. (Moscow, Russian Federation)</td>
</tr>
<tr>
<td>P-519</td>
<td>Hepatitis B immunoglobulin prophylaxis for prevention of de novo hepatitis B infection from hepatitis B core antibody-positive donors</td>
<td>Kyeongdeok Kim (Seoul, Korea, Republic of)</td>
</tr>
<tr>
<td>P-520</td>
<td>Early allograft dysfunction as a predictor for graft and patient survival after liver transplantation</td>
<td>Laura Mazilescu, Dr. (Toronto, Canada)</td>
</tr>
<tr>
<td>P-522</td>
<td>Gender and ethnicity disparity in liver transplantation for non-alcoholic fatty liver diseases associated hepatocellular carcinoma in the United States</td>
<td>Liyun Yuan, Assistant Professor of Clinical Medicine (Los Angeles, United States)</td>
</tr>
<tr>
<td>P-523</td>
<td>Outcomes from the use of pediatric livers with NAFLD</td>
<td>Malcolm MacConmara, MD (Dallas, United States)</td>
</tr>
<tr>
<td>P-524</td>
<td>Elderly patients who underwent ortotopic liver transplant more than 10 years ago and their resilience capacity</td>
<td>Felipe Alconchel (Murcia, Spain)</td>
</tr>
<tr>
<td>P-525</td>
<td>HBV and HCC recurrence after LT in a single transplant center</td>
<td>Martina Gambato, MD, PhD (Padova, Italy)</td>
</tr>
<tr>
<td>P-526</td>
<td>Long term liver transplant survivors</td>
<td>Ebru H. Ayvazoglu Soy (Ankara, Turkey)</td>
</tr>
<tr>
<td>P-528</td>
<td>Is home-based exercise therapy effective and feasible after liver transplant? A preliminary randomized controlled trial</td>
<td>Mohammad Javaherian (Tehran, Iran, Islamic Republic of)</td>
</tr>
<tr>
<td>P-529</td>
<td>Acute kidney injury as a major complication in Iranian orthotopic liver transplant recipients</td>
<td>Mohsen Nasiri Toosi (Tehran, Iran, Islamic Republic of)</td>
</tr>
<tr>
<td>P-530</td>
<td>How do tacrolimus levels change during pregnancy in liver transplant (LT) recipients? What are the consequences of these changes?</td>
<td>Mussarat Nazia Rahim (London, United Kingdom)</td>
</tr>
</tbody>
</table>
Scientific Programme

P-531 Long term outcome of patients undergoing LDLT for alcohol related liver disease  
Neeraj Saraf, Dr (Gururgam, India)

P-532 α-Lipoic acid improves the short-term outcomes in human liver transplantation: findings from the EXTEND study  
Paola Casciato (Buenos Aires, Argentina)

P-533 Liver transplantation in portal vein thrombosis: the experience and growth of a tertiary reference center in Mexico  
Paulina Carpinteyro-Espin, Dr. (Mexico City, Mexico)

P-534 Days alive and out of hospital following liver transplantation: impact of donor and recipient variables  
Peter Frasco, Consultant, Assistant Professor (Phoenix, United States)

P-535 Low TSC1 expression predicts poor prognosis and benefits from sirolimus in HCC patient undergoing LT  
Qianwei Ye (Hangzhou, China)

P-536 Diagnostic investigation of opportunistic infection post DCD liver transplantation based on immunologic monitoring  
Quan Zhuang (Changsha, China)

P-537 Long-term full adherence and high efficacy against HBV recurrence after liver transplantation by using long-life parenteral HBV-immunoglobulins (HBIG) in combination with oral antivirals  
Riccardo Volpes (Palermo, Italy)

P-538 Outcomes of customized outflow reconstruction techniques for left lateral segment grafts with anatomically complex hepatic veins in pediatric liver transplantation  
Sadhana Shankar (Chennai, India)

P-539 The impact of surgical technique on outcomes of liver transplantation after portal vein thrombosis: experiences from a large liver transplantation center  
Saman Nikeghbalian (Shiraz, Iran, Islamic Republic of)

P-540 Outcomes of liver transplantation for a rare cause of acute liver cell failure - Ratol (yellow phosphorus) poisoning  
Sathish Kumar (Chennai, India)

P-541 High-mobility group box 1 (HMGB1) as a prognostic marker for early allograft dysfunction and ischemic-type biliary lesions in human liver transplantation  
Shaojun Shi, MD. (Rotterdam, Netherlands)

P-542 Long term quality of life following liver transplantation in a developing country with a free health care system  
Suchintha Tillakaratne (Ragama, Sri Lanka)

P-544 Combined lung and liver transplantation: single institution experience and outcomes  
Teresa Diago Uso (Cleveland, United States)

P-545 Influence of serotonin on liver transplantation and postoperative outcome  
Tobias Zott (Vienna, Austria)
Scientific Programme

P-546 Living donor liver transplantation demonstrated superiority to deceased donor transplantation in long-term outcomes after adult liver transplantation; cumulative single-center retrospective cohort study of 19 years
Toru Goto (Toronto, Canada)

P-547 Outcomes in adult liver retransplantation from donation after brain death in patients with ischemic cholangiopathy
Verónica Guiomar, Dra. (Porto, Portugal)

P-549 Dynamic immune cell profiling reveals NK cell shift as dominant process in early allograft dysfunction after liver transplantation
Xinyu Yang (Hangzhou, China)

P-550 Acute kidney injury is an independent risk factor for major adverse cardiac events after living donor liver transplantation
YiChia Chan (Kaohsiung, Taiwan, Republic of China)

P-552 Verification of nutrition-based prognostic marker as a prognostic indicator in living donor liver transplantation
Yuki Imaoka (Hiroshima, Japan)

P-553 Late liver allograft dysfunction: frequency, types, risk factors
Yan Moysyuk, Prof. (Moscow, Russian Federation)

P-554 Perioperative mortality in liver transplantation before and after the implementation of Share 35
Zacharias Duus Holm, Medical Student (San Francisco, United States)

P-555 Diagnostic accuracy of liver stiffness measurement by fibroscan in liver transplant recipients
Zeynep Melekoğlu Ellik (Ankara, Turkey)

Surgical Video vPosters 1

vP-001 Right posterior sector living donor liver transplantation with double portal vein - donor hepatectomy and recipient implantation
Abdul Rahman Hakeem (Chennai, India)

vP-002 Extra-anatomical jump graft arterial reconstruction using a great saphenous vein autograft during living donor liver transplantation
Zhassulan Baimakhanov, MD, PhD (Almaty, Kazakhstan)

Surgical Video vPosters 2

vP-003 Advantages and limitations of swine LDLT model: new SNUH protocol
Kwong-Woong Lee (Seoul, Korea, Republic of)

vP-004 Pure laparoscopic donor right hepatectomy: using intracorporeal suture technique
Kyung-Suk Suh, MD, PhD (Seoul, Korea, Republic of)

Surgical Video vPosters 3

vP-005 Partial splenectomy on patients with portal hypertension/liver disease
Fidel Lopez-Verdugo, MD (Salt Lake City, United States)
Scientific Programme

vp-006 Living donor liver transplantation with double artery reconstruction and outflow angioplasty for Wilson’s disease
Xiangcheng Li (Nanjing, China)
Surgical Video vPosters 4

vp-008 Innovative technique avoiding bleeding after reperfusion in living donor liver transplantation using a modified right lobe graft
Allana Fortunato, MD (São Paulo, Brazil)
Surgical Video vPosters 5

vp-009 Laparoscopic cholecystectomy with indocyanine green guide fluorescent imaging is a feasible and safe approach even in liver transplantation recipient: a case report
Yi Ping Sng (Kaohsiung, Taiwan, Republic of China)

vp-010 The ALPPS procedure for the resection of large hepa-to cellular carcinoma with chronic hepatitis B condition
Madhusudhan Chinthakindi (Hyderabad, India)
Surgical Video vPosters 6

vp-011 Inferior vena cava replacement in living donor liver transplantation
Kamal Yadav (Gurugram, India)
Late Breaking Abstracts

LB P-001 Fibrinogen Concentration a Predictor for Transfusion Requirement in Liver Transplant Recipients
Vijay Vohra (Gurugram, India)

LB P-002 Use of Extracorporeal Membrane Oxygenation for Intraoperative Takatsubo Cardiomyopathy in Patient Undergoing Liver Transplantation
Elif Aybike Özmumcu (Istanbul, Turkey)

LB P-003 Intraoperative Management of Severe Hyponatremia during Live-Donor Liver Transplantation.
Marina Gitman, Assistant professor of clinical anesthes (Chicago, United States)

LB P-004 Ventricular arrhythmias during liver transplant in a patient with prolonged QT interval
Raed Al-kurwi, Clinical Fellow (London, Canada)

LB P-006 A case of HCV related CLD with multicentric HCC : reading between the lines
Taniya datta, Dr (Kolkata, India)

LB P-007 Inhibition of the FAS Pathway of Apoptosis with RNA Interference During Liver Machine Perfusion Preservation Reduces Ischemia Reperfusion Injury after Liver Transplantation
Eliano Bonaccorsi-Riani, MD, PhD (Brussels, Belgium)

LB P-008 Liver graft infrared thermography during living donor transplant procedure: first clinical cases
Alexander Sushkov (Moscow, Russian Federation)

LB P-009 Adverse impact of natural killer cells on human hepatocyte expansion in swine.
Erek Nelson (Rochester, United States)
**Scientific Programme**

**LB P-010**  
Simultaneous partial splenectomy during liver transplantation for liver cirrhotic patients combined with severe splenomegaly and hypersplenism  
Jiang Wentao (Tianjin, China)

**LB P-011**  
Treatment of portal-cava shunt vessels during the liver transplantation  
Dazhi Tian (Tianjin, China)

**LB P-012**  
Liver transplantation in the presence of portal vein thrombosis  Initial experience in the University of Athens  
Georgios Sotiropoulos, Professor Dr. (Athens, Greece)

**LB P-013**  
LIVER TRANSPLANTATION: PERI OPERATIVE DEATH AT A SINGLE CENTER  
Vincent De Pauw, Dr (Bruxelles, Belgium)

**LB P-014**  
Packing procedure effective in liver transplantation for hemophilic patients with HIV/HCV coinfection.  
Susumu Eguchi, Prof. (Nagasaki, Japan)

**LB P-015**  
Liver transplantation in a patient with dyskeratosis congenita: case report  
Milena Peruhova (Sofia, Bulgaria)

**LB P-016**  
Establishment of a predictive model of persistent hypersplenism after liver transplantation  
Qingjun Guo (Tianjin, China)

**LB P-017**  
DECEASED DONOR WITH MENINGITIS AND ENCEPHALITIS BE AWARE AND THINK TUBERCULOSIS  
Simone Perales, Msc (Campinas, Brazil)

**LB P-018**  
Extended hypothermic oxygenated machine perfusion enables ex situ preservation of porcine and human livers for up to 24 hours.  
Isabel Brüggenwirth (Groningen, Netherlands)

**LB P-019**  
Donor blood composition is a risk factor for biliary injury in donation after circulatory death liver transplantation  
Otto van Leeuwen (Groningen, Netherlands)

**LB P-020**  
Insights gathered from perfusate analysis during hypothermic oxygenated machine perfusion in liver transplantation  
Damiano Patrono (Torino, Italy)

**LB P-021**  
The use of cerium oxide nanoparticles during ex-situ normothermic perfusion in discarded human liver grafts  
Davide Ghinolfi, MD, PhD (Pisa, Italy)

**LB P-022**  
Analysis of the liver recovery rate in DCD donors preserved with Normothermic Regional Perfusion: Comparison with the “gold standard” DBD.  
Patricia Ruiz-Ordorica, Dr (Barakaldo, Spain)

**LB P-023**  
Mid-preservation ex situ normothermic machine perfusion of liver grafts: Concept for organ reconditioning hub  
Rohit Gaurav (Cambridge, United Kingdom)

**LB P-024**  
Attitudes and Barriers Towards Participation in the Process of DCD Donations Among Physician Anesthesiologists in a Academic Department  
Marina Moguilevitch, Associate Professor (Bronx, United States)
Scientific Programme

LB P-025  Effects of Simvastatin Donor Pretreatment on Graft Survival after Liver Transplantation: A Randomized Controlled Double-Blinded Trial.
Duilio Pagano, MD, PhD (Palermo, Italy)

LB P-026  The Liver Retransplantation Risk Score predicts long-term survival after adult liver retransplantation. An ELITA study based on the ELTR registry.
Isabel Brüggenwirth (Groningen, Netherlands)

LB P-028  Management of the donor affected by a Rare Disease. How to use livers ensuring compliance with the relative safety and quality of the transplant?
Daniela Peritore, MD (Roma, Italy)

LB P-029  ‘CHALLENGES IN LIVER TRANSPLANTATION FOR HEPATIC VASCULAR MALFORMATIONS’
Annalisa Dolcet (London, United Kingdom)

LB P-030  Outcome of live liver donor who is 75 years old (case)
Geun Hong (Seoul, Korea, Republic of)

LB P-031  Risk factor for initial poor graft function in orthotopic liver transplantation
Sungwon Jung (Gyeonggi-do, Korea, Republic of)

LB P-032  Use of Elderly Donors (>65 Years) for Liver Transplantation: a single center experience
Jisan Sun (Tianjin, China)

LB P-033  The results of pilot study of the mesenchymal stem cells local therapy efficiency for induction of immunosuppression in the early postoperative period after liver transplantation.
Sergey Korotkov (Minsk, Belarus)

LB P-034  Mammalian Target of Rapamycin Inhibitor Everolimus Reduces the Risk of Late Biliary Stenosis in Adult to Adult Liver Transplantation
Koray Kutluturk, Assistant Professor Dr (Malatya, Turkey)

LB P-035  PRESERVATION OF THE VASCULAR SUPPLY OF EXTRAHEPATIC BILIARY TREE REDUCES BILIARY COMPLICATION IN LIVING DONOR LIVER TRANSPLANTATION
Cemalettin Koç, Asst. Prof. MD (Malatya, Turkey)

LB P-036  RISK FACTORS FOR EARLY HEPATIC ARTERY THROMBOSIS AFTER ADULT TO ADULT LIVING DONOR LIVER TRANSPLANTATION
Koray Kutluturk, Assistant Professor Dr (Malatya, Turkey)

LB P-037  Dual graft living liver transplantation: a case report
Eryigit Eren (Istanbul, Turkey)

LB P-038  Liver transplantation for Niemann-Pick disease type B
Ümit Özçelik (Istanbul, Turkey)

LB P-039  Left lobe living donor liver transplantation in an adult patient with situs inversus totalis
Ümit Özçelik (Istanbul, Turkey)

LB P-040  Results of using the cystic duct for biliary reconstruction for multiple bile ducts in right lobe living donor liver transplantation
Eryigit Eren (Istanbul, Turkey)
Scientific Programme

LB P-041  Combining thrombectomy with intraoperative balloon dilatation for physiological portal inflow augmentation during liver transplantation in patients with Yerdel grade 3 portal vein thrombosis and stenosis  
Eryigit Eren (istanbul, Turkey)

LB P-042  Simple and an effective method: Use of omental flap for reconstruction of portal flow in living donor liver transplantation  
Mehmet Tokac (Istanbul, Turkey)

LB P-043  Hepatitis B immunoglobulin reduced cell proliferation, viability and stem-like characteristics of hepatocellular carcinoma cells in vitro and offers tumor control in vivo  
Keigo Machida (Los Angeles, United States)

LB P-044  Biliary complications in pediatric liver transplantation: criteria for failure of radiologic treatment  
Ana M. Calinescu (Geneva, Switzerland)

LB P-045  Biliary complications in pediatric liver transplantation: when surgical treatment is (still) needed  
Ana M. Calinescu (Geneva, Switzerland)

LB P-046  Use of porcine acellular dermal matrix for delayed abdominal wall closure after pediatric living donor liver transplantation. First case reported in Mexico.  
Luis Carlos Rodriguez Sancho (zapopan, Mexico)

LB P-047  Postoperative MELD as outcome predictor in early period after pediatric liver transplantation  
Yordanka Uzunova (Sofia, Bulgaria)

LB P-048  DOPPLER ULTRASONOGRAPHY BLOOD FLOW CHANGES OF THE HEPATIC ARTERY IN LIVER TRANSPLANTS COMPLICATED WITH CHOLANGITIS  
Ebru H. Ayyazoglu Soy (Ankara, Turkey)

LB P-049  D-MELD Score Effectively Predicts Post-Transplant Outcomes Following Liver Transplantation From Donation After Circulatory Death  
Haiyang Xie (Hangzhou, China)

LB P-050  Impact of physical activity on nutritional status in liver recipients  
Kseniia Kokina, PhD (Moscow, Russian Federation)

LB P-051  Outcomes of orthotopic liver transplantation for end-stage autoimmune liver disease: single center experience  
Jiang Li (Tianjin, China)

LB P-052  ARTERIAL CONDUITS IN LIVER TRANSPLANT: TWENTY YEARS EXPERIENCE IN PERÚ-ESSALUD  
Carlos Rondon Leyva, Dr. (LIMA, Peru)

Late Breaking Abstracts: Covid-19 and liver transplantation

LB P-054  Producing gene-edited pigs as bioreactors for human hepatocytes using recombinant adeno-associated viruses  
Mengyu Gao (Chengdu, China)

LB P-055  Are outcomes of living donor liver transplantation better during the COVID 19 Pandemic  
Jagadeesh Menon (Chennai, India)
Scientific Programme

LB P-056  Normothermic machine perfusion (NMP) to tackle COVID-19 related logistic delays in salvaging a right extended split liver graft - A case report.  
Manikandan Kathirvel (London, United Kingdom)

LB P-057  COVID-19 infection in liver transplant recipients: 2020 reported data from the main Liver Transplant Center in Romania  
Speranta Iacob (Bucharest, Romania)

LB P-058  Consequences of COVID-19 pandemic on pediatric liver transplantation in Japan.  
Masaki Yamada (Tokyo, Japan)

LB P-059  Impact of COVID-19 on the living donor liver transplantation programs in Japan  
Kaori Kuramitsu, MD (Kobe, Japan)

LB P-060  COMBINED LIVER AND KIDNEY TRANSPLANT IN A POST COVID INFECTION RECIPIENT : APPROACH AND CHALLENGES  
Ashish Malik, Senior Consultant (Delhi, India)

LB P-061  Running a Successful Living Donor Liver Transplant Program During the COVID-19 Pandemic  
Ashwin Rammohan (Chennai, India)

LB P-062  Timely access to pediatric liver transplantation during covid 19 pandemic : What can be done ?  
Jagadeesh Menon (Chennai, India)

LB P-063  Outcome of patients awaiting Deceased Donor Liver Transplantation during Covid-19 pandemic.  
Dinesh Jothimani, Dr (Chennai, India)

LB P-064  Veno-venous extracorporeal membrane oxygenation (V-V ECMO) for Coronavirus Disease 2019 (COVID-19) related refractory respiratory failure in liver transplantation (LT) recipients: A single centre experience  
Tasneem Pirani, Dr (London, United Kingdom)

LB P-065  Relaunching Living Donor Liver Transplantation, single center experience in heavily loaded COVID-19 country  
Hany Said abd Elbaset, Prof. (Cairo, Egypt)

LB P-066  Evaluation of anti-SARS CoV2 antibodies in liver transplant recipients.  
Suzana Calretas (Coimbra, Portugal)

Opening Session  
13:10 - 13:30  
Track 1

ILTS Today

At the 2021 Virtual Congress of ILTS, ELITA and LICAGE, we will start each day with a special format – ILTS TODAY.

Moderated by two members of the Vanguard Committee, the ILTS TODAY show will give you an overview of the day’s program. Each day, two special guests will join to highlight their favorite sessions as well as their career trajectory in liver transplantation.

Chairs:  
Moderator: Marit Kalisvaart, MD PhD (Zurich, Switzerland)  
Moderator: Ryan Chadha, MD (Jacksonville, United States)
Scientific Programme

**Guests**

Nancy Kwan Man, MBBS, PhD (Hong Kong, Hong Kong)
Yaman Tokat, MD, PhD (Istanbul, Turkey)

Pre-Meeting Symposium
13:30 - 17:15
Track 1

**Pre-Meeting Symposium: Living Donor Transplantation: Beyond Surgery**

**Chairs:**
Moderator: Mohamed Rela, MS, FRCS, DSc (Chennai, India)
Moderator: Yaman Tokat, MD, PhD (Istanbul, Turkey)
Co-Chair: Prashant Bhangui, MBBS, MS (Medanta, India)
Co-Chair: Deniz Balci, MD, PhD (Ankara, Turkey)

**Session 1: The LDLT Donor I**

Hiroto Egawa, MD, PhD (Tokyo, Japan)
Kyung-Suk Suh, MD, PhD (Seoul, Korea, Republic of)

**Accepting a steatotic right lobe living donor - Limits, preparation, and role of defatting cocktails**

Nazia Selzner, MD, PhD (Toronto, Canada)

**Safe use of low GRWR grafts**

Arvinder Singh Soin, MD (Gurugram, India)

**Debates in LDLT - Minimally invasive donor hepatectomy: Laparoscopic vs. robotic**

Ki-Hun Kim, MD, PhD (Seoul, Korea, Republic of)
Dieter Broering, MD, PhD (Riyadh, Saudi Arabia)

**Session 2: The LDLT Donor II**

Chung Mau Lo, MD, PhD (Hong Kong)
Julie K. Heimbach, MD (Rochester, United States)

**Complex biliary anatomy: Short- and long-term risks for the donor**

Yuji Soejima, MD, PhD (Fukuoka, Japan)

**Long term psychosocial follow-up of donors post donor hepatectomy: An essential aspect**

Elizabeth Pomfret, MD (Denver, United States)

**Coffee break**

14:20

14:46

15:01

15:14

13:10
Scientific Programme

15:27 Debates in LDLT: Arterial reconstruction: Microscope vs. Loupes - Does it make a difference?
Deniz Balci, MD, PhD (Ankara, Turkey)
Nam-Joon Yi, MD (Seoul, Korea, Republic of)

15:51 What matters in Small for Size Syndrome in LDLT: Portal flow and/or pressure
Cristiano Quintini, MD (Cleveland, United States)

Session 4: The LDLT Recipient II - Surgical Innovations in LDLT (Video Lectures)
Silvio Nadalin, MD (Tübingen, Germany)
Karim Halazun, MD (New York, United States)

16:15 Intraoperative management of PVT: Different scenarios, different solutions
Mohamed Rela, MS, FRCS, DSc (Chennai, India)

16:28 Bench reconstruction of complex venous outflow
Dong-Hwan Jung, MD, PhD (Seoul, Korea, Republic of)

16:41 Closing remarks
Kyung-Suk Suh, MD, PhD (Seoul, Korea, Republic of)

Pathology Workshop

Workshop
13:30 - 15:30
Track 2

13:30 Transplant oncology: Current status including tumor types and peri LT treatment, and future perspectives. What can a liver surgeon expect from a pathologist?
Gonzalo Sapisochin, MD, PhD, MSc (Toronto, Canada)

13:43 Tumor pathology of HCC, combined HCC-CCA, iCCA and metastatic tumor: Tumor diagnosis including diagnostic pitfalls, macro/micro classification and inter/intra tumoral heterogeneity
Mina Komuta, MD (Tokyo, Japan)

14:05 Chemotherapy-induced liver injury (steatohepatitis, NRH, SOS): Pathological features and clinical impact
Hanlin L. Wang, MD, PhD (Los Angeles, United States)

Non-Oncology Section
Scientific Programme

Diagnosis and assessment of disease severity as well as post LT recurrence in chronic liver disease patients. What can a liver surgeon expect from a pathologist?  
Taizo Hibi, MD (Kumamoto, Japan)  
14:20

Chronic liver diseases (viral hepatitis, AIH, PSC, PBC) and acute liver failure in pre- and post-LT patients  
Jimin (Nancy) Liu, MD (Oakville, Canada)  
14:33

Fatty liver diseases including (non) alcoholic- steatohepatitis : definition and pathological features in pre- and post-LT patients  
Xinyan Zhao, MD (Beijing, China)  
14:55

Group discussion  
15:10

Workshop  
13:30 - 16:30  
Track 3

Basic Science Workshop: From Clinical Liver Transplantation to Personalized Patient Care: Omics, Artificial Intelligence and Experimental Models

Chairs:
Moderator: Burcin Ekser, MD, PhD (Indianapolis, IN, United States)
Moderator: Kevin Tak-Pan Ng, PhD (Hong Kong, China)

The A_B_C of liver transplant research: Starting a lab for liver transplantation research, from basic science to precision medicine  
13:30

Basic science  
Nancy Kwan Man, MBBS, PhD (Hong Kong, Hong Kong)  
13:48

Translational science  
Timucin Taner, MD, PhD (Rochester, United States)  
14:06

Discussion  
14:15

The multi-omics era: Identifying strategies that will benefit specific research questions in liver transplantation  
Big data analyses  
Mamatha Bhat, MD (Toronto, Canada)  
14:33

Discussion  
14:42

What experimental models can I set up for personalized medicine?  
Small animal models  
Eliano Bonaccorsi-Riani, MD, PhD (Brussels, Belgium)  
15:00

Large animal models  
Paulo Martins, MD, PhD (Worcester, United States)  
15:18

Discussion  
15:27

New advances in liver transplantation science  
Jean-Charles Duclos-Vallee, MD, PhD (Paris, France)
Scientific Programme

How do I publish basic science papers in liver transplantation? - What is Transplantation Journal's position as the official journal of ILTS to accept basic science papers?
Carla Baan (Netherlands)

Discussion

Concurrent Oral Abstract Session
13:30 - 15:00

Concurrent Oral Abstract Session: Malignancies

Chairs:
Moderator: James Eason, MD (Memphis, United States)
Moderator: Sherrie Bhoori, MD (Milan, Italy)

O-069  Multimodal strategy for hepatocellular carcinoma in the elderly: to transplant or not to transplant
Marc Najjar (New York, United States)

O-070  The Dynamic Alfa-Fetoprotein Response (AFP-R) predicts outcome after liver transplantation for Hepatocellular Carcinoma (HCC): a multi-center international validation of the NYCA score in >2000 patients
Karim Halazun, MD (New York, United States)

O-071  International, multicenter study on the outcome of locoregional therapy before liver transplant for hepatocellular carcinoma extending the Milan criteria
Helena Degroote (Ghent, Belgium)

O-073  Usage of circulating tumor cells for tumor recurrence prognosis in liver transplantation patients with hepatocellular carcinoma
Maogen Chen (Guangzhou, China)

O-074  Pre-treatment lymphocyte status in HCC patients associates with DEB-TACE response and correlates with liver synthetic dysfunction and increased regulatory immune cells
Kelley Nunez (New Orleans, United States)

O-075  Postoperative trend and prognostic value of immuno-inflammatory and immuno-nutritional biomarkers, in liver transplanted patients for hepatocellular carcinoma
Riccardo Pravisani (Udine, Italy)

O-076  Impaired cholesterol metabolism predicts tumor recurrence after liver transplantation for hepatocellular carcinoma
Modan Yang (Hangzhou, China)

O-077  A combination of pre-operative PET positivity and MoRAL score can predict survival in patients with hepatocellular carcinoma recurrence after liver transplantation
Indah Jamtani, MD (Seoul, Korea, Republic of)

Discussion
Scientific Programme

Concurrent Oral Abstract Session
13:30 - 15:00

Concurrent Oral Abstract Session: Anesthesia/Critical Care Medicine/Acute Liver Failure

Chairs:
Moderator: Dmitri Bezinover, MD (Hershey, United States)
Moderator: Koen M.E.M. Reyntjens, MD (Groningen, Netherlands)

O-122 Simultaneous heart-liver-kidney transplantation: new frontiers in modern day transplantation
Govind Rangrass, Assistant Professor of Anesthesia/Critic (Chicago, United States)

O-123 HASI-iQUEST: investigating viral etiologies of acute liver failure of unknown cause
Nicolas Gille (Villejuif, France)

O-124 Meld-sodium is an independent predictor of response to corticosteroids and outcome in patients with severe forms of acute autoimmune hepatitis
Manuel Barbero, MD (Florencio Varela, Argentina)

O-125 Protocol on table extubation in small pediatric liver transplant recipients is not only feasible but also associated with better outcome
Vijay Kant Pandey (New Delhi, India)

O-126 Therapeutic coil embolization to aid liver transplantation in type II hepatopulmonary syndrome with severe hypoxemia
Ambreen Sawant, Dr (Mumbai, India)

O-127 Clinical benefits of renal replacement therapy in combination with hemoadsorption in patients with acute-on-chronic liver failure
Mihai Popescu (Bucharest, Romania)

O-128 Invasive fungal infections in liver transplant recipients
Madhumita Udayasankar, Dr. (Chennai, India)

O-129 Postoperative atrial fibrillation in patients undergoing liver transplantation: retrospective analysis of risk factors and outcomes
Eva Rivas (Cleveland, United States)

O-130 Reversal of vitamin K antagonists with prothrombin complex in patients undergoing liver transplantation: a single-centre experience
Samira Martinez Otero (Barcelona, Spain)

Discussion
Scientific Programme

SIG Meeting
15:30 - 17:00

SIG Meeting: ILTS SIG in Infectious Diseases and Liver Transplantation and TASL Joint Meeting: HOT Topics in Viral Infections (HCV, HBV and HEV) and Liver Transplantation

Chairs:
Moderator: Varvara Kirchner, MD (Minneapolis, United States)
Moderator: Ramazan Idilman, MD, PhD (Çankaya/Ankara, Turkey)

15:30
The use of HCV + donors into HCV negative recipients
Norah Terrault, MD (Los Angeles, United States)

15:50
Management of HBV before and after the liver transplantation
Bulent Degertekin, MD (Ankara, Turkey)

16:10
HEV infection following liver transplantation
Maria García Eliz, MD (Valencia, Spain)

16:30
Round table discussion
Ahmet Gurakar, MD (Baltimore, United States)
James Fung, MD (Hong Kong, Hong Kong)
Carmen Vinaixa, MD (Valencia, Spain)
Gökhan Kabaçam, MD (Ankara, Turkey)

SIG Meeting
15:30 - 17:00

SIG Meeting Precision Medicine and Biomarkers in Liver Transplantation: An Updated Guide for Research in Liver Transplantation - Translating Basic Discoveries to Clinical Excellence

Chairs:
Moderator: Nancy Kwan Man, MBBS, PhD (Hong Kong, Hong Kong)
Moderator: Amandeep Bajwa (Memphis, United States)

15:30
System biology and precision transplantation medicine: Challenges and future opportunities in liver transplantation
Valeria R. Mas, MS, PhD, FAST (Baltimore, United States)

15:45
Topic 1: Applying new concepts: Liver donor quality
Clinical Perspective: Bridging the gap, taking risks without affecting outcomes, and new technology advances supporting expansion of donor organ pool
Paolo Muiesan, MD, PhD (Birmingham, United Kingdom)

16:00
Basic and translational science perspective: Using new biomarkers for assessing donor organ quality - Moving toward composite scores
Malcolm MacConmara, MD (Dallas, United States)

16:15
Basic science perspective: Using organoids for tissue repair - Improving graft quality
Monique M.A. Verstegen, Dr. (Rotterdam, Netherlands)
Scientific Programme

Panel Discussion: Joining efforts in biomarker discovery and validation:
Biomarker Liver Transplant Network
16:30
Sunil M. Kurian, MD (La Jolla, United States)
Nancy Kwan Man, MBBS, PhD (Hong Kong, Hong Kong)
Valeria R. Mas, MS, PhD, FAST (Baltimore, United States)
Monique M.A. Verstegen, Dr. (Rotterdam, Netherlands)
Angela M Chen, MD (Indianapolis, IN, United States)
Isabel Brüggenwirth (Groningen, Netherlands)

Meet the Experts
17:15 - 17:45

Meet the Presidents
What makes ILTS so special? Why should you engage with the society? The current ILTS President Claus Niemann, the next ILTS President Marina Berenguer, and Mohamed Rela, President-elect will talk about their motivations to be an active part of ILTS, what they have already achieved, and their plans for the future of the society.

Guests
17:15
Claus Niemann, MD (San Francisco, United States)
Marina Berenguer, MD (Valencia, Spain)
Mohamed Rela, MS, FRCS, DSc (Chennai, India)

Industry Sponsored Session
17:45 - 18:45

SIG Meeting
18:45 - 20:15

SIG Meeting: DCD, Preservation & Machine Perfusion: The Results of the ILTS Special Interest Group Venice Consensus Meeting on DCD Liver Transplantation

Chairs:
Moderator: Jeroen de Jonge, MD, PhD (Rotterdam, Netherlands)
Moderator: Markus Selzner, MD (Toronto, Canada)

Introduction  • Summary of ILTS Consensus Conference on DCD and Machine Perfusion in Venice January 2020  • Recap of webinar activities of the SIG over the last year  • Future steps
Marit Kalisvaart, MD PhD (Zurich, Switzerland)
Amela Hessheimer, MD (Barcelona, Spain)

Benchmarks in DCD
19:05
Andrea Schlegel, MD (Birmingham, United Kingdom)

Strategies to use machine perfusion in DCD liver transplantation
19:25
Diethard Monbaliu, MD, PhD (Leuven, Belgium)

Discussion
19:45
Scientific Programme

SIG Meeting
18:45 - 20:15

SIG Meeting: Liver Transplant Oncology

Chairs:
Moderator: Christian Tosso, MD, PhD (Geneva, Switzerland)
Moderator: Mark R. Ghobrial, MD, PhD (Houston, United States)

- **Current status of SIG - members, projects, next steps**
  Taizo Hibi, MD (Kumamoto, Japan) 18:45

- **Active prospective studies in transplant oncology around the world**
  Julie K. Heimbach, MD (Rochester, United States) 19:00

- **Collaborative studies in transplant oncology through ILTS**
  Gonzalo Sapisochin, MD, PhD, MSc (Toronto, Canada) 19:15

- **Medical approaches and immunogenomics in transplant oncology**
  Milind Javle, MD (Houston, United States) 19:30

- **Discussion** 19:45

SIG Meeting
18:45 - 20:15

SIG Meeting Liver Transplant Immunology: Immune Checkpoint Inhibitors for Cancer Therapy - Risk and Benefit After Liver Transplantation

Chairs:
Moderator: John Bridgwater, MD, PhD (London, United Kingdom)
Moderator: Timucin Taner, MD, PhD (Rochester, United States)

- **Molecular diagnosis of rejection post-LT with a pediatric focus**
  Juliet Emamaullee, MD, PhD (Los Angeles, United States) 18:45

- **Risk of rejection after the transplant: Monitor for immune activation**
  Alberto Sanchez Fueyo, MD (London, United Kingdom) 19:00

- **Cancer immunotherapy: Mechanism – benefit – toxicity**
  Maria Londoño, MD, PhD (Spain) 19:15

- **Immune checkpoint inhibitors after LT for de novo tumor: PRO and CON - Clinical case presentation**
  Eleonora De Martin, MD (Villejuif, France) 19:30

- **Discussion** 19:45
Scientific Programme

SIG Meeting
18:45 - 20:15

SIG Meeting: Cardiovascular Topics in Liver Transplantation

Chairs:
Moderator: Samuel Lee, MD, FRCPC (Calgary, Canada)
Moderator: James Findlay, MD (Rochester, United States)

18:45
Brief informal introduction of our SIG
James Findlay, MD (Rochester, United States)
Christopher Wray, MD (Los Angeles, United States)

18:50
Current era of coronary artery evaluation in liver transplant candidates: Out with the old in with the new?
Lisa VanWagner, MD, MSc (Chicago, Illinois, United States)

19:08
Intraoperative CV collapse: Avoiding the near-death experience
Ryan Chadha, MD (Jacksonville, United States)

19:26
Post-transplant heart failure: Can it be predicted or prevented?
Manhal Izzy, MD (Nashville, United States)

19:44
Assessment of congestive hepatopathy in adults undergoing heart transplantation: Utility of MELD-XI, elastography, and liver biopsy
Douglas A. Simonetto, MD (Rochester, Minnesota, United States)

Q&A
20:02

Concurrent Oral Abstract Session
18:45 - 20:15

Concurrent Oral Abstract Session: Late Breaking Abstracts II - Challenges in liver transplantation in the covid era

Chairs:
Moderator: Varvara Kirchner, MD (Minneapolis, United States)
Moderator: Timothy Pruett, MD (Minneapolis, United States)

LB O-07
Changes in Humoral Immune Response after SARS-CoV-2 Infection in Liver Transplant Recipients Compared to Immunocompetent Patients
Aranzazu Caballero Marcos (Madrid, Spain)

LB O-08
T cell response in immunosuppressed redo-liver transplant recipients after COVID-19 infection and after first dose of vaccine against SARS-CoV-2
Jessica Lovatt (Leeds, United Kingdom)

LB O-09
Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients
Joris Blondeel, MD (Leuven, Belgium)

LB O-10
Impact of the COVID Pandemic in a High Volume Pediatric Liver Transplant Program in Brazil
Flavia Feier (Porto Alegre, Brazil)
### Scientific Programme

<table>
<thead>
<tr>
<th>LB O-11</th>
<th>The impact of SARS-CoV2 infection in pediatric liver transplant recipients: an international observational registry study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Noelle Ebel, Assistant Professor (Palo Alto, United States)</td>
</tr>
<tr>
<td>LB O-12</td>
<td>COVID 19: Awareness and concerns among parents of pediatric liver transplant recipients</td>
</tr>
<tr>
<td></td>
<td>Jagadeesh Menon (Chennai, India)</td>
</tr>
<tr>
<td>LB O-13</td>
<td>Liver transplant recipients with Covid-19 infection: results from an Italian multicenter cohort</td>
</tr>
<tr>
<td></td>
<td>Chiara Mazzarelli, MD (Milano, Italy)</td>
</tr>
<tr>
<td>LB O-14</td>
<td>Liver transplant recipients infected with Sars-CoV-2 in the early versus late postoperative period: is there a difference in outcomes?</td>
</tr>
<tr>
<td></td>
<td>Marisa Rafaela Damasceno Lima, MD (São Paulo, Brazil)</td>
</tr>
<tr>
<td>LB O-15</td>
<td>Successful liver transplantation in a patient with acute liver failure and acute COVID-19 infection</td>
</tr>
<tr>
<td></td>
<td>Kristen, M Kidson, Dr. (Vancouver, Canada)</td>
</tr>
<tr>
<td>LB O-16</td>
<td>The impact of SARS-CoV-2 Pandemic on global liver transplant (LT) practices during the first wave: EASL-ESOT/ELITA-ILTS multi-society survey</td>
</tr>
<tr>
<td></td>
<td>Varvara Kirchner, MD (Minneapolis, United States)</td>
</tr>
</tbody>
</table>

#### Discussion

20:05

---

### ILTS Wrap-Up

What did you miss today? Each day, members of the Vanguard Committee will give you an overview of the highlights and learnings of the day.

**Chairs:**
Moderator: Varvara Kirchner, MD (Minneapolis, United States)
Moderator: Gökhan Kabaçam, MD (Ankara, Turkey)
Moderator: Albert Chi Yan Chan, MD (Hong Kong, Hong Kong)
Scientific Programme

Thursday, 06 May 2021

Opening Session
13:10 - 13:30

ILTS Today

At the 2021 Virtual Congress of ILTS, ELITA and LICAGE, we will start each day with a special format – ILTS TODAY.

Moderated by two members of the Vanguard Committee, the ILTS TODAY show will give you an overview of the day’s program. Each day, two special guests will join to highlight their favorite sessions as well as their career trajectory in liver transplantation.

Chairs:
Moderator: Gonzalo Sapisochin, MD, PhD, MSc (Toronto, Canada)
Moderator: Youngin Yoon (Seoul, Korea, Republic of)

Guests
13:10
Markus Selzner, MD (Toronto, Canada)
Valeria R. Mas, MS, PhD, FAST (Baltimore, United States)

Featured Symposium
13:30 - 15:00

Featured Symposium: Anesthesia/Critical Care

Chairs:
Moderator: Terry Pan, MBBS, FANZCA, FAMS, MHPE (Singapore)
Moderator: Annabel Blasi, MD, PhD (Barcelona, Spain)

Obesity and LT: New prospective
13:30
Jacek Cywinski, MD (Cleveland, United States)

High-risk donor liver transplantation: Perioperative challenges and outcome
13:45
David Kramer, MD (Milwaukee, United States)

Sarcopenia and nutritional status in LT: Criteria for not pursuing transplantation
14:00
Constantine Karvellas, MD (Edmonton, Canada)

Cerebral hemodynamic in cirrhosis
14:15
Ricardo Ulises Macías-Rodríguez, MD, PhD (Mexico, Mexico)

Open discussion
14:30
Scientific Programme

Featured Symposium
13:30 - 15:00

**Featured Symposium: Machine Perfusion: Do We Have the Answer?**

**Chairs:**
Moderator: Markus Selzner, MD (Toronto, Canada)
Moderator: Peter Friend, MD, FRCS (Oxford, United Kingdom)

- **Overview of current clinical machine perfusion strategies**
  Robert Porte, MD, PhD, FEBS (Groningen, Netherlands)
  13:30

- **General or selective use: Which grafts require machine perfusion?**
  Cristiano Quintini, MD (Cleveland, United States)
  13:45

- **Graft viability testing and treatment options during normothermic machine perfusion vs. hypothermic machine perfusion**
  Christopher Watson, MD (Cambridge, United Kingdom)
  Philipp Dutkowski, MD (Zurich, Switzerland)
  14:00

- **The essentials for future clinical trial designs in machine perfusion**
  Paulo Martins, MD, PhD (Worcester, United States)
  14:30

**Discussion**
14:45

Featured Symposium
13:30 - 15:00

**Featured Symposium: Diagnostics and Therapeutic Interventions**

**Chairs:**
Moderator: Jan Lerut, MD, PhD (Brussels, Belgium)
Moderator: Giuliano Testa, MD, FACS, MBA (Dallas, United States)

- **To stent or not to stent the bile duct**
  Abhinav Humar, MD (Pittsburgh, United States)
  13:30

- **HCC radioembolization vs transarterial chemoembolization - the ongoing battle**
  Ramazan Kutlu, MD (Malatya, Turkey)
  13:45

  **Pro**
  Gi-Young Ko, MD, PhD (Seoul, Korea, Republic of)
  14:00

  **Con**
  Deniz Balci, MD, PhD (Ankara, Turkey)
  14:15

**Pre-operative surgical planning using 3D simulation**
14:30

**Open discussion**
Scientific Programme

Vanguard Sessions
13:30 - 15:00

**Vanguard Featured Symposium**

**Chairs:**
Moderator: Ryan Chadha, MD (Jacksonville, United States)
Moderator: Gökhan Kabaçam, MD (Ankara, Turkey)

- **Risk stratification and prediction of mortality in LT for ACLF**
  13:30
  James Fung, MD (Hong Kong, Hong Kong)

- **Preoperative organ optimization for neurological renal and pulmonary system before LT in ACLF**
  13:45
  Isabel Campos Varela, MD (Spain)

- **Living donor selection in high urgency situation for ACLF**
  14:00
  Albert Chi Yan Chan, MD (Hong Kong, Hong Kong)

- **Debate: Should LDLT be performed for alcohol-induced ACLF**

  **Yes**
  14:15
  Tomohiro Tanaka, MD, PhD (Iowa City, United States)

  **No**
  14:30
  Timothy Pruett, MD (Minneapolis, United States)

- **Discussion**
  14:45

**LICAGE Parallel Symposium**
15:15 - 16:45

**LICAGE/Anesthesia/Critical Care Parallel Symposium: Pre-op**

**Chairs:**
Moderator: Gianni Biancofiore, MD (Pisa, Italy)
Moderator: Dana Tomescu, MD, PhD (Bucharest, Romania)

- **Peri-operative sodium and LT: Should we manage it or should we let it go?**
  15:15
  Dmitri Bezinover, MD (Hershey, United States)

- **Do we transplant patient with ACLF 3?**
  15:30
  Julie K. Heimbach, MD (Rochester, United States)

- **Timing of dialysis in AKI - early vs. late?**
  15:45
  Mitra Nadim, MD, FASN (United States)

- **Cardiomyopathies in ESLD: Screening, management and contraindication for LT**
  16:00
  James Findlay, MD (Rochester, United States)

- **Discussion**
  16:15
Scientific Programme

Plenary Abstract Session
15:15 - 16:45

Track 2

Plenary Session I

Chairs:
Moderator: Elizabeth Pomfret, MD (Denver, United States)
Moderator: Prashant Bhangui, MBBS, MS (Medanta, India)

O-061 15:15
Hyponatremia is associated with increased mortality in pediatric patients on the waiting list for liver transplantation
Dmitri Bezinover, MD (Hershey, United States)

O-060 15:23
Radiomics to predict aggressive hepatocellular carcinoma features in liver transplantation
Tommy Ivanics, MD (Toronto, Canada)

O-062 15:31
Delayed kidney transplant (KT) up to 2 days in combined liver-kidney transplantation (CLKT) offers similar renal function as KT alone: comparison analysis with mate kidneys
Burcin Ekser, MD, PhD (Indianapolis, IN, United States)

O-063 15:39
Proteinase3 contributes to hepatic ischemia reperfusion injury through promoting neutrophil inflammatory response
Chang Xian Li (Nanjing, China)

O-064 15:47
Liver transplant, liver resection or ablation as first-line treatment for solitary HCC 3 cm or less: an Intention-to-treat analysis
Tommy Ivanics, MD (Toronto, Canada)

O-065 15:55
Reassessment of the risk of recurrence (R3) after liver transplantation for HCC: validation of the R3 score and comparison with existing models
Charlotte Costentin (Grenoble, France)

O-066 16:03
Time-trends in patient mortality and graft survival of patients receiving a DCD or DBD liver transplantation in the UK and Ireland between 2008 and 2016
David Wallace, Clinical Research Fellow (London, United Kingdom)

O-067 16:11
Post-normothermic perfusion sepsis: defining a new clinical syndrome
David Nasralla (Oxford, United Kingdom)

Discussion 16:19

Track 3

EDI Session: Is Diversity Alone Enough for Equity?

Chairs:
Moderator: Claire Francoz, MD, PhD (Clichy, France)
Moderator: Gabriela A. Berlakovich, MD, FEBS (Vienna, Austria)

What are scientific journals doing about gender & diversity? 15:15
Jennifer Sargent, MD (London, United Kingdom)
Scientific Programme

**Burnout in medicine. How to care for ourselves while caring for others?**
Colin P. West, MD, PhD, FACP (Rochester, United States)  
**Racial difference & navigation toward the top**
Amal Aqul, MD (Dallas, United States)
**Discussion**

**Featured Symposium**
15:15 - 16:45  
**Featured Symposium: The Digital Liver Transplant Patient**

**Chairs:**
Moderator: John Roberts, MD (San Francisco, United States)  
Moderator: Daniel Maluf, MD (Memphis, United States)

**Real-time quality assessment**
Ryutaro Hirose, MD (San Francisco, United States)

**Big Data? Big help or hype?**
Dimitri Aristotle Raptis, MD, MSc, PhD (London, United Kingdom)

**Robotics as an emerging technology in transplant surgery**
Yee Lee Cheah, MD (Burlington, United States)

**Innovative applications for long-term quality control**
Jon J. Snyder, MD, PhD (Minneapolis, United States)

**Open discussion**

**Meet the Experts**
17:00 - 17:30  
**Woman 2 Woman**
At Woman 2 Woman, Nazia Selzner and Nancy Ascher will discuss how to succeed as a woman in the medical world, particularly in the setting of liver transplantation. Although one might think gender disparity is no longer an issue, experience has taught us otherwise. Nancy Ascher’s incredible career is a true inspiration for breaking down the borders which women still face.

**Chairs:**
Moderator: Nazia Selzner, MD, PhD (Toronto, Canada)

**Guests**
Nancy L. Ascher, MD, PhD (San Francisco, United States)

**Industry Sponsored Session**
17:30 - 18:30  
**Industry Sponsored Session**
Scientific Programme

Concurrent Oral Abstract Session
18:30 - 20:00

Concurrent Oral Abstract Session: Living Donor Transplantation

Chairs:
Moderator: Yaman Tokat, MD, PhD (Istanbul, Turkey)
Moderator: Ashwin Rammohan, MD, MBBS (Chennai, India)

O-033  The significance of DSA and chronic antibody mediated rejection after pediatric living donor liver transplantation
Seiichi Shimizu, MD, PhD (Setaygaya-ku, Japan)
18:30

O-034  Multifactorial effect of hepatocyte growth factor (HGF) on the microscopic regeneration of liver allograft in recipients who underwent transplantation from living donors
B. Handan Ozdemir (Ankara, Turkey)
18:38

O-035  Living donor liver transplantation results in superior patient and graft survival when compared to deceased donor liver transplantation: a systematic review and meta-analysis
Juliet Emamaullee, MD, PhD (Los Angeles, United States)
18:46

O-036  The first fully automated liver volumetry for preparation of living liver donation using methods of artificial intelligence
Arzu Oezcelik (Essen, Germany)
18:54

O-037  Solving the 'multiple arterial inflow conundrum' in living donor liver transplantation
Yogesh Puri (Chennai, India)
19:02

O-038  Biliary complications after single- and dual-graft living-donor liver transplantation using a right posterior section graft from a donor with a type III portal vein variation
Byung Gon Na (Seoul, Korea, Republic of)
19:10

O-039  Transplant benefit in HCC patients with PVTT downstaged using radiotherapy: a new ray of hope?
Prashant Bhangui, MBBS, MS (Medanta, India)
19:18

O-040  Effect of simultaneous splenectomy in adult living donor liver transplantation analyzed using propensity score matching
Tomoharu Yoshizumi, Associate Professor (Fukuoka, Japan)
19:26

O-041  Comparative analysis of histopathological variables and biliary senescence in liver allograft rejection in different time zones post Living donor liver transplantation
Archana Rastogi, Addl. Prof. (Delhi, India)
19:34

Discussion
19:42
Scientific Programme

Concurrent Oral Abstract Session
18:30 - 20:00

Track 2

Concurrent Oral Abstract Session: Donation after Cardiac Death and Machine Perfusion

Chairs:
Moderator: Burcin Taner, MD (Jacksonville, United States)
Moderator: Andrea Schlegel, MD (Birmingham, United Kingdom)

O-042  Liver transplantation outcomes for Maastricht category-III donors after circulatory death: static cold storage vs in situ normothermic regional perfusion vs ex situ normothermic machine perfusion 18:30
Rohit Gaurav (Cambridge, United Kingdom)

O-043  Histopathological grade of ischemia reperfusion injury on short- and long-term outcomes in liver transplantation using DCD (deceased after circulatory death donor) grafts 18:38
Annalisa Dolcet (London, United Kingdom)

O-044  Normothermic machine perfusion of the Liver to Enable transplantation in difficult recipients (NAPLES) 18:46
Siobhan McKay (Birmingham, United Kingdom)

O-045  Disparities in the use of DCD liver allografts from donors 60 years or older in the US vs. the UK. A joined NHSBT/ SRTR analysis 18:54
Emmanouil Giorgakis, Assistant Professor (Little Rock, United States)

O-046  Hypothermic machine perfusion improves DCD liver graft quality through GSTM1-mediated cytochrome P450 exogenous substance metabolism pathway 19:02
Wenjin Liang, MD (Hubei, China)

O-047  DCD outcomes after normothermic liver perfusion 19:10
David Nasralla (Oxford, United Kingdom)

O-049  Opportunities to expand utilization of pediatric DCD donors - a role for normothermic machine perfusion? 19:26
Malcolm MacConmara, MD (Dallas, United States)

O-050  Outcomes after Controlled Oxygenated Rewarming of human livers before transplantation 19:34
Dieter Paul Hoyer, PD Dr. (Essen, Germany)

Discussion 19:42

Concurrent Oral Abstract Session
18:30 - 20:00

Track 3

Concurrent Oral Abstract Session: Basic Science/Translational Research

Chairs:
Moderator: Mamatha Bhat, MD (Toronto, Canada)
Moderator: Timucin Taner, MD, PhD (Rochester, United States)
Scientific Programme

O-015  Liver immune remodeling after transplantation: an insight on donor-recipient crosstalk in a murine model
Haitao Huang (Hangzhou, China)

O-016  Hepatocellular carcinoma 3D bioprinted model with 7 days of sorafenib perfusion: modeling the cancer microenvironment's chemotherapy response
Angela M Chen, MD (Indianapolis, IN, United States)

O-017  Multiplexed imaging mass cytometry analysis reveals a new role for CD68+ macrophages in chronic liver transplantation rejection
Juliet Emamaullee, MD, PhD (Los Angeles, United States)

O-018  Blocking PD-L1 accelerates postoperative hepatic regeneration in small-for-size liver through M1 macrophage polarization
Ji-Hua Shi (Zhengzhou, China)

O-020  Intravenous administration of mitochondria minimizes liver ischemia reperfusion injury in lean and diet induced obese mice
Amandeep Bajwa (Memphis, United States)

O-021  Hepatic IR injury induced de-differentiation of neutrophils which exacerbated graft inflammation
Yum Hung Fredrick Cheng (Hong Kong, Hong Kong)

O-022  The molecular diagnosis of rejection in liver transplant biopsies: first results of the INTERLIVER study
Katelynn S. Madill-Thomsen (Edmonton, Canada)

O-023  Alternatively-activated plasmacytoid dendritic cells promote post-transplant hepatocellular carcinoma recurrence via adenosine A1 receptor
Li Pang (Hong Kong, Hong Kong)

Discussion

Concurrent Oral Abstract Session
18:30 - 20:00

Track 4

Concurrent Oral Abstract Session: Immunosuppression and Tolerance Induction

Chairs:
Moderator: Ignacio M Gonzalez-Pinto, MD, PhD (Oviedo, Spain)
Moderator: Gabriela A. Berlakovich, MD, FEBS (Vienna, Austria)

O-051  Tolerant liver transplant patients have higher level of Y RNA fragments in the circulation
Canan Kuscu (Memphis, United States)

O-052  Long-term incidence of de novo malignancies after liver transplantation and weaning off immunosuppression: the Tor Vergata results from an observational study
Carlo Gazia, MD (Rome, Italy)
Scientific Programme

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-053</td>
<td>Hsa-miR-372-3p/AGPS and APOC4 axis participates in rapamycin-induced dyslipidemia after liver transplantation</td>
<td>Guanghan Fan (Hangzhou, China)</td>
<td>18:46</td>
</tr>
<tr>
<td>O-054</td>
<td>Comparison of immune status of patients receiving liver transplantation and kidney transplantation at single-cell level: a preliminary study</td>
<td>Bo Peng, Dr. (Changsha, China)</td>
<td>18:54</td>
</tr>
<tr>
<td>O-055</td>
<td>Population pharmacokinetics of meltdose tacrolimus (Envarsus®) in stable adult liver transplant recipients</td>
<td>Maaike Biewenga (Leiden, Netherlands)</td>
<td>19:02</td>
</tr>
<tr>
<td>O-056</td>
<td>Randomised trial of sustained release tacrolimus Vs twice daily tacrolimus in adult LDLT</td>
<td>Guhan Venkatakrishnan (Kochi, India)</td>
<td>19:10</td>
</tr>
<tr>
<td>O-057</td>
<td>Tacrolimus to cyclosporine conversion in liver transplant recipients: safe or unsafe?</td>
<td>Vaibhav Patil, Dr. (Chennai, India)</td>
<td>19:18</td>
</tr>
<tr>
<td>O-059</td>
<td>Role of novel immunosuppressive CD10+ antigen-presenting neutrophils in promoting HCC tumorgenesis</td>
<td>Yum Hung Fredrick Cheng (Hong Kong, Hong Kong)</td>
<td>19:26</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td></td>
<td>19:34</td>
</tr>
</tbody>
</table>

Industry Sponsored Session
18:30 - 20:00

Industry Workshop

Closing Session
20:00 - 20:15

ILTS Wrap-Up

What did you miss today? Each day, members of the Vanguard Committee will give you an overview of the highlights and learnings of the day.

Chairs:
- Moderator: Uzung Yoon (Philadelphia, United States)
- Moderator: Eleonora De Martin, MD (Villejuif, France)
- Moderator: Tomohiro Tanaka, MD, PhD (Iowa City, United States)
Scientific Programme

Friday, 07 May 2021

Opening Session
13:10 - 13:30

ILTS Today

At the 2021 Virtual Congress of ILTS, ELITA and LICAGE, we will start each day with a special format – ILTS TODAY.

Moderated by two members of the Vanguard Committee, the ILTS TODAY show will give you an overview of the day’s program. Each day, two special guests will join to highlight their favorite sessions as well as their career trajectory in liver transplantation.

Chairs:
Moderator: Amelia Hessheimer, MD (Barcelona, Spain)
Moderator: Ashwin Rammohan, MD, MBBS (Chennai, India)

Guests
Fuat H. Saner, MD, PhD (Essen, Germany)
Wojciech Polak, MD, PhD (Rotterdam, Netherlands)

LICAGE Parallel Symposium
13:30 - 15:00

LICAGE/Anesthesia/Critical Care Parallel Symposium: Intra-op

Chairs:
Moderator: Fuat H. Saner, MD, PhD (Essen, Germany)
Moderator: Ashish Malik, MD (New Delhi, India)

Prevention and management of intra-operative fibrinolysis: Controversy and new trends
Annabel Blasi, MD, PhD (Barcelona, Spain)

Haemodynamic goals and intra-operative management of systemic hemodynamics
Linda Liu, MD (San Francisco, United States)

Intra-operative cardiac disasters
Gebhard Wagener, MD (New York, United States)

Intra-operative management of pulmonary hypertension
Christopher Wray, MD (Los Angeles, United States)

Discussion

Page 58 / 76
Scientific Programme

ELITA Featured Symposium
13:30 - 15:00

ELITA and TASL Joint Symposium I: HBV and Liver Transplantation

Chairs:
Moderator: Ahmet Gurakar, MD (Baltimore, United States)
Moderator: Silvio Nadalin, MD (Tübingen, Germany)

What is the role and rational for HBIG in prevention of HBV recurrence in 2021

Clinical case presentation 13:30
Lydia Sastre, MD (Barcelona, Spain)

Discussion and key points. 13:38
Zeki Karasu, MD (Izmir, Turkey)

HBIG-free NA-based monoprophylaxis: Who and when?

Clinical case presentation 13:48
Martina Gambato, MD, PhD (Padova, Italy)

Discussion and key points. 13:56
James Fung, MD (Hong Kong, Hong Kong)

Key points of the ELITA HBV and LT Practice Guidelines 14:06
Christophe Duvoux, MD (Créteil, France)

Clinical investigation in HBV LT candidates: Assessment of the evidence and future prospects 14:24
Norah Terrault, MD (Los Angeles, United States)

Open discussion 14:42

Parallel Symposium
13:30 - 15:00

Parallel Session for Pediatrics I: Liver Transplantation for Pediatric Metabolic Liver Diseases

Chairs:
Moderator: Mureo Kasahara, MD, PhD (Tokyo, Japan)
Moderator: Paolo Muiesan, MD, PhD (Birmingham, United Kingdom)

Management and indication of liver transplantation for urea cycle disease and organic acidemia 13:30
Anil Dhawan, MBBS, MD, FRCPCH (London, United Kingdom)

Liver transplantation in PFIC 1 13:45
Udeme D. Ekong, MD, MPH (New Haven, United States)

Considerations for auxiliary liver transplantation in pediatric metabolic liver disease 14:00
Mohamed Rela, MS, FRCS, DSc (Chennai, India)
Scientific Programme

Organ bio-engineering based on liver scaffold technology for liver failure 14:15
Hiroshi Yagi, Prof (Tokyo, Japan)

Open discussion 14:30

Featured Symposium
13:30 - 15:00

Featured Symposium: Topics Without Consensus

Chairs:
Moderator: James Pomposelli, MD, PhD (Denver, United States)
Moderator: Federico Guillermo Villamil, MD (Buenos Aires, Argentina)

Acute alcoholic hepatitis 13:30
Audrey Coilly, MD (Paris, France)

Recreational drug use /opioid use in transplant patients 13:45
Susan Orloff, MD (Portland, United States)

Obesity and frailty: Mutually exclusive? 14:00
Rahima Bhanji, MD, MSc, FRCPC (Edmonton, Canada)

Plasma Exchange/Artificial liver support: a bridge or substitute to LT for acute liver failure 14:15
Shiv Kumar Sarin, MD, DM, DSc (New Delhi, India)

Open discussion 14:30

Vanguard Sessions
13:30 - 14:30

Vanguard Grand Round Case Presentations

Chairs:
Moderator: Marina Berenguer, MD (Valencia, Spain)
Moderator: Marit Kalisvaart, MD PhD (Zurich, Switzerland)

Successful re-transplant for primary non-function on maximal life support including VAV ECMO 13:30
Juliet Emamaullee, MD, PhD (Los Angeles, United States)
Michael Spiro, MD (London, United Kingdom)

Use of Extracorporeal Membrane Oxygenation for Intraoperative Takatsubo Cardiomyopathy in Patient Undergoing Liver Transplantation 13:45
Elif Aybike Özumcu (Istanbul, Turkey)
Ryan Chadha, MD (Jacksonville, United States)

Assessment of interstitial graft glucose metabolism with microdialysis as a tool for early hepatic artery thrombosis diagnosis 14:00
Alexander Sushkov (Moscow, Russian Federation)
David Victor, MD (Houston, United States)
Scientific Programme

Discussion 14:15

LICAGE Parallel Symposium 15:15 - 16:45

LICAGE/Anesthesia/Critical Care Parallel Symposium: Post-op

Chairs:
Moderator: Hüseyin Ilksen Toprak, MD (Malatya, Turkey)
Moderator: Marina Moguilevitch, Associate Professor (Bronx, United States)

Management of failing graft 15:15
Fuat H. Saner, MD, PhD (Essen, Germany)

Graft-versus-host disease in LT - Something we can learn from bone marrow transplantation 15:30
Emrah Otan, MD (Malatya, Turkey)

Management of postoperative infections 15:45
Emmanuel Weiss (Paris, France)

Hemostatic changes in cirrhotic patients with sepsis 16:00
Ecaterina Scarlatescu, MD, PhD (Bucharest, Romania)

Discussion 16:15

ELITA Featured Symposium 15:15 - 16:45

ELITA Symposium II: Acute on Chronic Liver Failure and LT

Chairs:
Moderator: Kymberly Watt, MD (Rochester, United States)
Moderator: Wojciech Polak, MD, PhD (Rotterdam, Netherlands)

Introduction: ELITA CLIF European retrospective cohort on ACLF 15:15
Luca Belli, MD (Milan, Italy)

The issue of futility: Are ACLF grade 3 patients too sick to be transplanted? 15:30
Faouzi Saliba (Villejuif, France)

Prognosis of ACLF in patients listed for transplantation: Timing and implications for organ allocation in the MELD era 15:45
Rajiv Jalan, MD, PhD (London, United Kingdom)

Surgical challenges in liver transplantation for ACLF: Is partial grafting (split and LDLT) a reasonable option? 16:00
Roberto Troisi, MD, PhD, FEBS (Gent, Belgium)

ACLF in LT candidates: A challenge for intensivists and anesthesiologists 16:15
William Bernal, MD, FRCP, FFICM (London, United Kingdom)
Scientific Programme

Discussion

Parallel Symposium
15:15 - 16:45

Parallel Session for Pediatrics II: Pediatric Liver Transplantation with Extrahepatic Involvements

Chairs:
Moderator: Manuel Rodriguez-Davalos, MD (Salt Lake City, United States)
Moderator: Mohamed Rela, MS, FRCS, DSc (Chennai, India)

- **When is liver and kidney transplantation a necessity in pediatric setting?**
  Nam-Joon Yi, MD (Seoul, Korea, Republic of)

- **Fontan-associated liver cirrhosis: Role of the liver transplant surgeon**
  C. Andrew Bonham, MD (Palo Alto, United States)

- **Hepatopulmonary syndrome in pediatric liver transplantation**
  Cigdem Arikan, MD (Istanbul, Turkey)

Open discussion

Plenary Abstract Session
15:15 - 16:45

Plenary Session II

Chairs:
Moderator: Bijan Eghtesad, MD (Cleveland, United States)
Moderator: James Findlay, MD (Rochester, United States)

- **O-140 Predicting graft function after liver transplantation: validating the role of lactate at the end of transplant**
  Alessandro M. Galli, MD (San Francisco, United States)

- **O-141 Single-cell RNA sequencing reveals gene expression profiling of ischemia reperfusion injury**
  Linhe Wang (Guangzhou, China)

- **O-142 Sarco-model, a novel score to better predict the risk of death in cirrhotic patients awaiting liver transplantation**
  Quirino Lai (Brussels, Belgium)

- **O-143 Pure laparoscopic versus open right hepatectomy in live liver donors: a propensity score matched analysis**
  Suk Kyun Hong (Seoul, Korea, Republic of)

- **O-144 Clonal evolution of recurrent hepatocellular carcinoma post-transplant and dependence on the immune environment**
  Mamatha Bhat, MD (Toronto, Canada)
Scientific Programme

O-145  Myeloid-derived suppressor cells mobilization through CXCL1-CXCR2 signaling facilitates tumor recurrence after liver transplantation  15:55
Yuewen Wang, Dr. (Hong Kong, Hong Kong)

O-146  CT based sarcopenia assessment & frailty scores are better than PELD in predicting early morbidity and mortality after pediatric live donor liver transplantation  16:03
R.V Sugi Subramaniam, Clinical Fellow (Chennai, India)

O-147  The efficacy of ischemia-free liver transplantation in the treatment of end-stage liver disease in a prospective, randomized, controlled trial: a report of first 25 cases  16:11
Xiao-Shun He (Guangzhou, China)

O-148  Survival outcomes after liver transplantation for intrahepatic cholangiocarcinoma  16:19
Joy Nolte Fong (Houston, United States)
Mark R. Ghobrial, MD, PhD (Houston, United States)

Discussion  16:27

Vanguard Sessions
15:15 - 16:15  Track 5

Vanguard Surgical Video Session

Chairs:
Moderator: Ashwin Rammohan, MD, MBBS (Chennai, India)
Moderator: Gonzalo Sapisochin, MD, PhD, MSc (Toronto, Canada)

The RAPID concept - Marriage between ALPPS and liver transplantation  15:15
Deniz Balci, MD, PhD (Ankara, Turkey)

Left lobe with caudate LDLT - Graft retrieval and venous outflow reconstruction  15:30
Nobuhisa Akamatsu, PhD (Tokyo, Japan)

Drone technology for organ procurement - Are we ready for the prime time?  15:45
Joseph Scalea, MD (Baltimore, United States)

Discussion  16:00

Meet the Experts
17:00 - 17:30  Track 1

Developing Liver Transplantation Programs worldwide

This session will revolve around developing liver transplantation programs. Roberto Hernandez will discuss with Prashant Bhangui and Alfred Kow about the current situations in different countries, the challenges, and the road forward.

Chairs:
Moderator: Roberto Hernandez-Alejandro, MD (Rochester, United States)
Scientific Programme

17:00

**Guests**
Prashant Bhangui, MBBS, MS (Medanta, India)
Alfred Wei Chieh Kow, MD (Singapore, Singapore)
Nicolas Goldaracena, MD (Toronto, Canada)

Concurrent Oral Abstract Session
17:30 - 19:00

**Track 1**

Concurrent Oral Abstract Session: Surgical Videos for Technical Innovation

**Chairs:**
Moderator: Arvinder Singh Soin, MD (Gurugram, India)
Moderator: Nam-Joon Yi, MD (Seoul, Korea, Republic of)

**O-105**
Robotic right hepatectomy for living donor liver transplantation
Dieter Broering, MD, PhD (Riyadh, Saudi Arabia)
17:30

**O-106**
Pediatric liver transplantation for hepatoblastoma with extended tumor thrombi into right atrium under veno-venous bypass
Mureo Kasahara, MD, PhD (Tokyo, Japan)
17:38

**O-107**
Pediatric liver transplantation - segment 3 and segment 2 monosegment grafts
Abdul Rahman Hakeem (Chennai, India)
17:46

**O-108**
Laparoscopic extended right hepatectomy in a living donor
Youngin Yoon (Seoul, Korea, Republic of)
17:54

**O-109**
Living donor liver transplantation using right anterior graft in donors with expected small remnant volume and anatomic variations
Kyung-Suk Suk (Seoul, Korea, Republic of)
18:02

**O-110**
Unified management of IVC web and right hepatic vein in LDLT for membranous obstruction of vena cava (Budd Chiari syndrome)
Yang Won Nah (Ulsan, Korea, Republic of)
18:10

**O-111**
Living donor liver transplantation with caval replacement and re-implantation of right renal vein for secondary Budd-Chiari syndrome due to IVC leiomyosarcoma
Abdul Rahman Hakeem (Chennai, India)
18:18

Discussion
18:34

Concurrent Oral Abstract Session
17:30 - 19:00

**Track 2**

Concurrent Oral Abstract Session: Oncology/Radiology

**Chairs:**
Moderator: Ramazan Kutlu, MD (Malatya, Turkey)
Moderator: Hatem Khalaf (Doha, Qatar)
Scientific Programme

O-131 Diagnostic value of heterogeneity index and SUVmax for grading of HCC in PET/MRI
Bahattin Özkul, Dr. (Istanbul, Turkey) 17:30

O-132 Diagnostic accuracy of MRI diffusion-weighted imaging heterogeneity index value in staging HCC at explant: correlation with fluorine-18-fluorodeoxyglucose standardised uptake value
Bedriye Koyuncu Sokmen (Istanbul, Turkey) 17:38

O-133 Can neoadjuvant local ablation be an alternative to liver transplantation for hepatocellular carcinoma patients?
Ebru H. Ayvazoglu Soy (Ankara, Turkey) 17:46

O-134 Imaging features and diagnostic accuracy of MRI in combined hepatocellular carcinoma (HCC-CCA)
Marc Najjar (New York, United States) 17:54

O-135 Cholangiocyte phenotype is an independent risk factor for hepatocellular carcinoma recurrence and poor survival after liver transplantation
Shi Feng (Hangzhou, China) 18:02

O-136 Complement components C3a promoted tumor recurrence after liver transplantation
Wai Ho Oscar Yeung (Hong Kong, China) 18:10

O-137 Chemoembolization and radio-embolization are similarly effective in achieving successful HCC down-staging: results from Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium
Neil Mehta, MD, Dr. (San Francisco, United States) 18:18

O-138 Metabolism reprogramming during conventional versus ischemia-free liver transplantation
Zhiyong Guo (Guangzhou, China) 18:26

O-139 Venous outflow congestion is related to poor recurrence-free survival of living donor liver transplantation recipients with hepatocellular carcinoma
Jinsoo Rhu (Seoul, Korea, Republic of) 18:34

Discussion 18:42

Concurrent Oral Abstract Session
17:30 - 19:00
Track 3

Concurrent Oral Abstract Session: Pediatrics

Chairs:
Moderator: Qiang Xia, Prof. (Shanghai, China)
Moderator: Varvara Kirchner, MD (Minneapolis, United States)

O-097 Practical utility of serum ammonia in children with acute liver failure; a biomarker of outcome
Hala Abdullatif (Cairo, Egypt) 17:30
Scientific Programme

O-098  Split liver transplantation: 20-year experience at a single high volume pediatric transplant center
Caroline Lemoine (Chicago, United States) 17:38

O-099  Outcomes of liver transplantation for pediatric recipients with progressive familial intrahepatic cholestasis
Kshetra Rinaldhy, dr (Chennai, India) 17:46

O-100  Neurological complications in pediatric liver transplant recipients: an analysis of risk factors and outcomes
Jagadeesh Menon (Chennai, India) 17:54

O-101  International Liver Transplantation Society Global Census report: a first look at the pediatric liver transplantation activity around the world
Fidel Lopez-Verdugo, MD (Salt Lake City, United States) 18:02

O-102  Efficacy of intraoperative cine-portogram to evaluate portosystemic collateral pathways in pediatric living donor liver transplantation
Hajime Uchida (Tokyo, Japan) 18:10

O-103  The largest single center report on pediatric liver transplantation: experiences and lessons learned
Saman Nikeghbalian (Shiraz, Iran, Islamic Republic of) 18:18

O-104  Failure-to-rescue rate as a measure of quality of care in an evolving paediatric liver transplantation unit: an eight-year study
Joseph Valamparampil (Chennai, India) 18:26

Discussion 18:34

Concurrent Oral Abstract Session
17:30 - 19:00  Track 4

Concurrent Oral Abstract Session: Short and Long-Term Patient and Allograft Outcomes I

Chairs:
Moderator: Manhal Izzy, MD (Nashville, United States)
Moderator: Nazia Selzner, MD, PhD (Toronto, Canada)

O-078  The small for size syndrome conundrum; spleen size rather than graft weight hold the key
Akanand Singh, MD, PhD (Kathmandu, Nepal) 17:30

O-079  Development of novel multivariable logistic regression model for predicting graft failure within 2 weeks and 4 weeks after liver transplantation using post-transplantation laboratory values
Jinsoo Rhu (Seoul, Korea, Republic of) 17:38

O-080  Functional changes in metabolic and malignancy-associated bacterial genes in the post-transplant intestinal microbiome
Mamatha Bhat, MD (Toronto, Canada) 17:46
Scientific Programme

O-081  Recurrence after liver transplantation for primary sclerosing cholangitis (PSC)- Japanese nationwide survey  
Nobuhisa Akamatsu, PhD (Tokyo, Japan)  
17:54

O-082  Outcomes following liver transplantation in obese recipients in the UK - a study over four decades  
Trishan Vaikunthanathan (London, United Kingdom)  
18:02

O-083  Utility of symmetric dimethylarginine in predicting future renal failure in liver transplant recipients  
Manhal Izzy, MD (Nashville, United States)  
18:10

O-084  Alcohol recurrence and outcome in patients transplanted for alcoholic cirrhosis: impact of the 6 months rule  
Faouzi Saliba (Villejuif, France)  
18:18

O-085  Results of a prospective pilot program for transplantation of patients with alcohol-related liver disease and less than 6 months abstinence  
Nazia Selzner, MD, PhD (Toronto, Canada)  
18:26

O-086  Is living donor liver transplantation a reasonable option for patients with acute-on-chronic liver failure? Results from a high-volume referral center  
Khalid Bzeizi, Dr. (Riyadh, Saudi Arabia)  
18:34

Discussion  
18:42

Concurrent Oral Abstract Session  
17:30 - 19:00

Concurrent Oral Abstract Session: A Potpourri of Liver Transplantation  
Track 5

Chairs:  
Moderator: Burcin Ekser, MD, PhD (Indianapolis, IN, United States)  
Moderator: Abraham Shaked, MD, PhD (Philadelphia, United States)

O-087  Role of amphiregulin signaling in mitochondrial biogenesis after partial liver transplantation  
Zhi Zhong (Charleston, United States)  
17:30

O-090  Hepatocyte polyploidy spectrum assists in prognostic stratification following liver transplant for hepatocellular carcinoma  
Liang Zhang, MD (Hangzhou, China)  
17:38

O-091  The use of stereotactic body radiation therapy as bridging therapy offered better local control and reduced dropout in hepatocellular carcinoma patients on liver transplant waitlist  
Tiffany CL Wong, MD (Hong Kong, Hong Kong)  
17:46

O-093  Taking liver transplant to “The Friendly Skies”: a novel pilot program using commercial flights and ride-sharing apps to minimize dry-run expenses and maximize DCD donors  
Gregory John McKenna (Dallas, United States)  
18:02
Scientific Programme

O-094  Recommendations for the safe use of G6PD deficient donors in living donor liver transplantation - analysis of outcomes in 59 donors over 6 years  18:10
Krishna Pradeep, Dr (Chennai, India)

O-095  Combined drug approach to prevent ischemia-reperfusion injury during transplantation of livers (CAPITL): results of a single-blinded randomized placebo-controlled trial  18:18
Markoen Mertens (Leuven, Belgium)

Discussion  18:26

Closing Session
19:00 - 19:15  Track 1

ILTS Wrap-Up
What did you miss today? Each day, members of the Vanguard Committee will give you an overview of the highlights and learnings of the day.

Chairs:
Moderator: Michael Spiro, MD (London, United Kingdom)
Moderator: Carmen Vinaixa, MD (Valencia, Spain)
Moderator: Oya Andacoglu, Assistant Professor of Surgery (Bronx, United States)
Scientific Programme

Saturday, 08 May 2021

Opening Session
13:10 - 13:30

ILTS Today

At the 2021 Virtual Congress of ILTS, ELITA and LICAGE, we will start each day with a special format – ILTS TODAY.

Moderated by two members of the Vanguard Committee, the ILTS TODAY show will give you an overview of the day’s program. Each day, two special guests will join to highlight their favorite sessions as well as their career trajectory in liver transplantation.

Chairs:
Moderator: David Victor, MD (Houston, United States)
Moderator: Isabel Campos Varela, MD (Spain)

Guests
Bijan Eghtesad, MD (Cleveland, United States)
Paolo Muiesan, MD, PhD (Birmingham, United Kingdom)

Featured Symposium
13:30 - 15:00

Featured Symposium: Transplant Oncology

Chairs:
Moderator: Mark R. Ghobrial, MD, PhD (Houston, United States)
Moderator: Chao-Long Chen, PhD (Kaohsiung, Taiwan, Republic of China)

Transplant immunology links to transplant oncology
Milind Javle, MD (Houston, United States)

Update on neoadjuvant strategies for liver cancer (CC and HCC)

Surgical perspective
Christian Toso, MD, PhD (Geneva, Switzerland)

New treatment options
John Bridgewater, MD, PhD (London, United Kingdom)

Discussion on Advanced ICCA - Transplant or resection?

Surgical resection
Parissa Tabrizian, MD, MSc (New York, United States)

Transplant
Gonzalo Sapisochin, MD, PhD, MSc (Toronto, Canada)

Discussion
Featured Symposium: Maintaining Excellence

Chairs:
Moderator: Henrik Petrowsky, MD, FACS (Zurich, Switzerland)
Moderator: Roberto Hernandez-Alejandro, MD (Rochester, United States)

What are the requirements of fellowship training: Lessons to learn from established transplant systems

**Surgery**
Susan Orloff, MD (Portland, United States)

**Hepatology**
Patrizia Burra, MD, PhD (Padua, Italy)

**Discussion**
Alfred Wei Chieh Kow, MD (Singapore, Singapore)
Patrizia Burra, MD, PhD (Padua, Italy)
Eduardo de Souza Martins Fernandes, MD (Rio de Janeiro, Brazil)
Susan Orloff, MD (Portland, United States)

The effects of regulations on fellowship training - Panel discussion

**Surgery**
Albert Chi Yan Chan, MD (Hong Kong, Hong Kong)
Julie K. Heimbach, MD (Rochester, United States)

**Hepatology**
Patrizia Burra, MD, PhD (Padua, Italy)
Gökhan Kabaçam, MD (Ankara, Turkey)

**Critical Care/Anesthesia**
Dmitri Bezinover, MD (Hershey, United States)
Christine Nguyen-Buckley (Los Angeles, United States)

**Open discussion**

What are the expectations of the trainees instructors and mentors?

**Fellow perspective**
Michael Linecker, MD, PhD (Zurich, Switzerland)

**Program director perspective**
Johnny C. Hong, MD, FACS (Milwaukee, United States)

**Discussion**
Scientific Programme

Featured Symposium
13:30 - 15:00

**Featured Symposium: Liver Transplantation in 2021**

**Chairs:**
Moderator: Simone Strasser, PhD (Sydney, Australia)
Moderator: Yaman Tokat, MD, PhD (Istanbul, Turkey)

- **Does Meld/Na Meld remain a useful allocation system in 2021?**
  Francois Durand, MD, PhD (Paris, France)  
  13:30

- **Protocols in immunosuppression after three decades: When and how?**
  Paolo De Simone, MD (Pisa, Italy)  
  13:45

- **What are new treatment options for Small for Size Syndrome in 2021?**
  Toru Ikegami, MD (Fukuoka, Japan)  
  14:00

- **Impact of liver donation on quality of life**
  Whitney Jackson, MD (Aurora, United States)  
  14:15

**Open discussion**  
14:30

Vanguard Sessions
13:30 - 14:30

**Vanguard Debate Session**

**Chairs:**
Moderator: David Victor, MD (Houston, United States)
Moderator: Varvara Kirchner, MD (Minneapolis, United States)

- **Machine perfusion pump is indicated for all marginal organs**  
  13:30

  - Yes
    Amelia Hessheimer, MD (Barcelona, Spain)

  - No
    Michael Spiro, MD (London, United Kingdom)

- **Early post-operative care in liver transplantation is best managed by surgeons or hepatologists**  
  13:50

  - Surgeon
    Prashant Bhangui, MBBS, MS (Medanta, India)

  - Hepatologist
    Eleonora De Martin, MD (Villejuif, France)

- **Defining the altruistic liver donation - Do or don’t?**  
  14:10

  - Do
    Nicolas Goldaracena, MD (Toronto, Canada)

  - Don’t
    Carmen Vinaixa, MD (Valencia, Spain)
Scientific Programme

Rising Star Symposium
15:15 - 16:45

Rising Star Plenary Session

Chairs:
Moderator: Nancy Kwan Man, MBBS, PhD (Hong Kong, Hong Kong)
Moderator: Claus Niemann, MD (San Francisco, United States)

O-001 Clinical and immunopathological features of two distinctive types of plasma-cell rich hepatitis: plasma-cell rich rejection and autoimmune hepatitis
Brian Horwich (Los Angeles, United States)
Jeffrey Kahn, MD (Los Angeles, United States)

O-002 Myosteatosis and its impact on graft- and patient survival in adult recipients of deceased donor liver transplantation
Zoltan Czigany, M.D. Ph.D. (Aachen, Germany)
Georg Lurje, MD (Berlin, Germany)

O-003 TLR4 induced PD-1 expression on myeloid dendritic cells promotes post-transplant HCC recurrence
Li Pang (Hong Kong, Hong Kong)
Nancy Kwan Man, MBBS, PhD (Hong Kong, Hong Kong)

O-004 Plasma microbiome profiles of liver transplant patients with operational tolerance
Joseph F Pierre (Memphis, United States)
Valeria R. Mas, MS, PhD, FAST (Baltimore, United States)

O-005 The beneficial intention-to-treat survival effect of living donation in patients with hepatocellular cancer waiting for liver transplantation
Quirino Lai (Brussels, Belgium)
Jan Lerut, MD, PhD (Brussels, Belgium)

Discussion

Concurrent Oral Abstract Session
17:00 - 18:30

Concurrent Oral Abstract Session: Short and Long-Term Patient and Allograft Outcomes II

Chairs:
Moderator: Shekhar Kubal, MD, PhD (Indianapolis, United States)
Moderator: Francois Durand, MD, PhD (Paris, France)

O-113 2019 refined criteria for cirrhotic cardiomyopathy predict post liver transplant cardiac events
Manhal Izzy, MD (Nashville, United States)

O-114 Prophylaxis of HBV recurrence after LT: economic impact of new ELITA guidelines
Paolo Cortesi (Monza, Italy)
### Scientific Programme

**O-115** Characterization of gut microbiome in liver transplant recipients with non-alcoholic steatohepatitis  
Joseph F Pierre (Memphis, United States)  
17:16

**O-116** Characteristics, trends and outcomes of liver transplantation (LT) for primary sclerosing cholangitis (PSC) in female patients: analysis of the European Liver Transplantation Registry (ELTR)  
Marina Berenguer, MD (Valencia, Spain)  
17:24

**O-117** Simple score to assess cardiovascular risk post-liver transplantation  
Tommaso Di Maira (Valencia, Spain)  
17:32

**O-118** An effective bridging tips technique to liver transplantation for Budd-Chiari syndrome  
Fatih Boyvat, MD, PhD (Ankara, Turkey)  
17:40

**O-119** Early portal vein thrombosis after liver transplant - interventional radiology may be the answer  
Shahnawaz Bashir, Dr (New Delhi, India)  
17:48

**O-120** Predictive factors of symptomatic nodular regenerative hyperplasia after liver transplantation  
Ilias Kounis (Villejuif, France)  
17:56

**O-121** Pregnancy in liver transplant recipients: understanding the risk of foetal growth restriction  
Mussarat Nazia Rahim (London, United Kingdom)  
18:04

**Discussion**  
18:12

---

Concurrent Oral Abstract Session  
17:00 - 18:30  
Track 2

### Concurrent Oral Abstract Session: Donor Selection Criteria/Patient Selection/Organ Allocation

**Chairs:**  
Moderator: Jiri Fronek, MD, PhD, FRCS (Praha, Czech Republic)  
Moderator: Tiffany CL Wong, MD (Hong Kong, Hong Kong)

**O-006** Random forest analysis of liver transplantation: the importance of organ failures  
Cyrille Feray, pr (Villejuif, France)  
17:00

**O-007** LIVERCOLOR: an algorithm quantification of liver graft steatosis using machine learning and color image processing  
Concepción Gómez-Gavara, PhD (Barcelona, Spain)  
17:08

**O-010** Liver transplantation with grafts from super obese donors with a BMI >50  
Paola Vargas (Charlottesville, United States)  
17:24

**O-011** Proposal and validation of a liver graft discard score for liver transplantation: a multicentre Italian study  
Fabio Melandro (Rome, Italy)  
17:32
## Scientific Programme

### O-013  
**An integrated model with donor gene polymorphisms predicts the fibrosis after liver transplantation**  
Chao Wang (Hangzhou, China)

### O-014  
**Bridging the gap: normothermic perfusion of discarded livers significantly alleviates the donor shortage in the United States**  
Siavash Raigani (Boston, United States)

### Discussion

---

**Concurrent Oral Abstract Session**  
17:00 - 18:30  
**Track 3**

### Concurrent Oral Abstract Session: Comorbidities, Infections, Complications

**Chairs:**  
Moderator: Claire Francoz, MD, PhD (Clichy, France)  
Moderator: Sanjiv Saigal, MD (Gurgaon, India)

<table>
<thead>
<tr>
<th>O-024</th>
<th>Impact of Multidrug resistance bacteria infections after liver transplantation on patient outcome and associated risk factors from a large cohort</th>
<th>17:00</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jules Fatseas (Villejuif, France)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-025</th>
<th>Timing of bariatric surgery for obese liver transplant candidates</th>
<th>17:08</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rashikh Choudhury (Aurora, United States)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-027</th>
<th>Frailty as predictive factor for waitlist mortality and survival after liver transplantation especially for patients with MELD≤15</th>
<th>17:16</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Christian Georg Klein, MD (Essen, Germany)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-028</th>
<th>Identification of novel exosomal miRNAs associated with HBV reactivation after liver transplantation</th>
<th>17:24</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Wenqi Qiu (Hong Kong, Hong Kong)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-029</th>
<th>A recent diagnosis of tuberculosis is a risk factor for post-transplant morbidity &amp; mortality after liver transplantation - a propensity score match-based analysis</th>
<th>17:32</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pradez Sapkota, Dr. (Chennai, India)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-030</th>
<th>The limited role of liver transplantation on reversal of porto-pulmonary hypertension pathology</th>
<th>17:40</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Junshi Doi (Cleveland, United States)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-031</th>
<th>Medication-related problems in liver transplant patients in the Netherlands</th>
<th>17:48</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Midas B Mulder (Rotterdam, Netherlands)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-032</th>
<th>One-year cardiovascular outcomes after a prospective and systematic cardiac risk evaluation of liver transplant recipients</th>
<th>17:56</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sonia Pascual, MD (Alicante, Spain)</td>
<td></td>
</tr>
</tbody>
</table>

### Discussion

18:04
Scientific Programme

Concurrent Oral Abstract Session
17:00 - 18:30

Concurrent Oral Abstract Session: Late Breaking Abstracts I

Chairs:
Moderator: Roberto Hernandez-Alejandro, MD (Rochester, United States)
Moderator: Marit Kalisvaart, MD PhD (Zurich, Switzerland)

LB O-01  100 consecutive cDCD liver transplantations preserved with normothermic regional perfusion. A unicentric experience.
Patricia Ruiz-Ordorica, Dr (Barakaldo, Spain)  17:00

LB O-02  Relationship between CPET variable and long term outcome
Jacob Lewis (Leeds, United Kingdom)  17:08

LB O-03  Sequential locoregional abdominal perfusion and ex-situ end-ischemic machine perfusion in DCD liver grafts with extremely prolonged warm ischemia time: dual-hypothermic versus normothermic machine perfusion
Davide Ghinolfi, MD, PhD (Pisa, Italy)  17:16

LB O-04  Use of artificial intelligence as innovative method for liver graft macrosteatosis assessment
Claire Goumard (Paris, France)  17:24

LB O-05  Auxiliary two-staged partial resection liver transplantation (ASPIRE-LTx) using living-donated left lobes to overcome small-for-size situation in adults/adolescents with end-stage liver disease
Stefan M. Brunner, Prof. Dr. (Regensburg, Germany)  17:32

LB O-06  Pre-liver transplant (LT) kidney function no longer affects post-LT survival in the modern transplant era: A 2 decades single center experience
Hani Wadei, Associate Professor of Medicine (Jacksonville, United States)  17:40

Discussion  17:48

State of the Art Lecture
18:30 - 19:00

State of the Art III

Chairs:
Moderator: Patrizia Burra, MD, PhD (Padua, Italy)

Men and women: Not the same patient  18:30
Marina Berenguer, MD (Valencia, Spain)
Scientific Programme

Meet the Experts
19:00 - 19:30

Career advice

How should you build your career in the field of liver transplantation? Join Marina Berenguer discussing with Elizabeth Pomfret and Valeria Mas about their experiences and best practices. This discussion will give young specialists valuable input in career planning.

Chairs:
Moderator: Marina Berenguer, MD (Valencia, Spain)

Guests
Elizabeth Pomfret, MD (Denver, United States)
Valeria R. Mas, MS, PhD, FAST (Baltimore, United States)

The best of ILTS
19:30 - 20:30

Best of ILTS

Chairs:
Moderator: Bijan Eghtesad, MD (Cleveland, United States)
Moderator: Gabriela A. Berlakovich, MD, FEBS (Vienna, Austria)

Introduction
Bijan Eghtesad, MD (Cleveland, United States)
Gabriela A. Berlakovich, MD, FEBS (Vienna, Austria)

Best of Surgery
Elizabeth Pomfret, MD (Denver, United States)

Best of Hepatology
Didier Samuel, MD (Villejuif, France)

Best of Anesthesiology
James Findlay, MD (Rochester, United States)

Closing Session
20:30 - 20:45

ILTS Wrap-Up

Chairs:
Moderator: Marina Berenguer, MD (Valencia, Spain)
Moderator: Mohamed Rela, MS, FRCS, DSc (Chennai, India)
Moderator: Yaman Tokat, MD, PhD (Istanbul, Turkey)